Can COVID-19 infect you twice? Mystery cases show how little is known about the virus – National Post

Everyone wants the virus that causes COVID-19 to be a one-and-done. But reports from South Korea are raising the possibility that infections can be reactivated, or that the infected, once recovered, could be infected anew.

At least 110 people in South Korea have tested positive for the pandemic virus after having been thought cured, according to reports. The World Health Organization told Reuters on Saturday the agency is working hard to get information on the cases.

Its believed the virus may have reactivated in some people, as opposed to them being re-infected all over again, or that repeat testing may simply be picking up harmless fragments of virus genetic material that can linger for weeks or months after a person recovers.

It could also come down to nothing more than faulty testing.

There are many different hypotheses

Canadian health officials are trying to verify the information from South Korea. I think there are many different hypotheses, Dr. Theresa Tam, Canadas chief public health officer, said Monday. Tam said its important to get our international partners to expand more on what is actually happening and maybe, yes, having an international collaboration in terms of looking at what happens to someone who has initially been infected.

We actually dont know if a test positive means that there is any viable virus in that particular person. Thats one of the first questions to actually answer, Tam said.

But the mystery cases illustrate just how little is known about the virus how the human body actually mounts an immunity and what actually happens in the longer term, Tam said. That could hamper the herculean efforts being poured into developing vaccines and, in the absence of a vaccine, make natural herd immunity harder to achieve.

Reports from Seoul describe people who tested negative for COVID-19 using PCR (polymerase chain reaction) testing who, some days later, tested positive again.

According to top U.S. infectious disease expert Dr. Anthony Fauci, advisor to the U.S. presidential COVID-19 task force, how long immunity lasts remains unknown. However, in an interview with the editor of the Journal of the American Medical Association, Fauci said the virus isnt changing much, and that the working assumption, although there is not 100 per cent certainty, is that if we get infected in February or March and recover, that next September, October, the person whos infected, I believe, is going to be protected.

While most people in the medical and scientific community share that thinking, wed be foolish to think we know everything about this virus, given that we have only known about its existence for about four months, cautioned Dr. Isaac Bogoch, an infectious diseases physician and scientist with the Toronto General Hospital.

What proportion of people get immunity, to what extent do they have immunity, and how long immunity lasts are still unanswered questions, Bogoch said. When we hear about people being reinfected it obviously raises a few red flags.

Bogoch believes that the most likely explanation is that the recovered patients tested positive using PCR (polymerase chain reaction) testing, which detects viral RNA, because they still carry some residual virus in the areas being swabbed, typically the back of the nose and throat. It doesnt mean theyre contagious to others, or that the viral fragments are capable of causing disease. The test may be positive for days, even weeks after people have recovered from an infection.

Another possibility is that some people who were initially told they were positive werent positive, but then became positive. And of course, the third possibility that we really hope is unlikely is that there is either reinfection or reactivation of the virus, Bogoch said. Obviously, we hope thats an unlikely scenario. But I think it still warrants exploration.

With reactivation, the virus triggers another eruption, the way the virus that initially causes chicken pox, varicella zoster, can come back years later as shingles.

I think these are remote, but not impossible scenarios, Bogoch said. Given that the virus is so new to humans, we should at least be open-minded to other possibilities, he said.

Dr. Anand Kumar, a critical care doctor at Winnipeg Health Sciences Centre, said PCR tests have a certain sensitivity. Some viruses, like herpes, can get inside cells, go into a latent phase and then pop out again under stress. But coronavirus isnt known to be one of them.

True reinfection is possible, Kumar said. But they dont say the amount of time between the (South Koreans) being cleared and the time they became positive again.

Without seeing any kind of academic paper, the idea of people bouncing back from negative to positive would likely come down to a testing issue, added Dr. Mark Loeb, a professor of pathology and molecular medicine at McMaster University in Hamilton.

If someone has had a natural infection, its likely that they would be immune, at least in the short term, Loeb said. Its not proven, though. Were dealing with likelihoods right now. Is it likely? I think its likely. Is it certain? No.

Email: skirkey@postmedia.com | Twitter:

Link:

Can COVID-19 infect you twice? Mystery cases show how little is known about the virus - National Post

COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market – Xconomy

XconomyNational

If Peter Marks had a magic wand to perfect the sophisticated process that takes a new vaccine from idea to reality, the US could have a way to prevent some people from COVID-19 infection in nine months to one year.

In the real world, the journey to a vaccine OKd under emergency guidelines is more likely to take 12 to 18 months, said Marks, who runs the FDAs Center for Biologics Evaluation and Research, on a Friday teleconference hosted by the Commonwealth Fund and the Alliance for Health Policy Teleconference for Media and Policymakers.

Marks said factors that will play a role in FDAs issuance of an emergency use authorizationnot an approvalwill include the level of coronavirus circulating, how well the vaccine works, and how safe it appears. Some of the data to back up safety and efficacy claims are likely to come from less traditional sources, such as adaptive trials, or those designed to allow changes along the way in response to early results, and real-world evidence.

Facilitating the development of a vaccine for COVID-19 is an agency priority now and for the foreseeable future since the US will likely see a second wave or even third wave [of infections] if we dont get it right and get it right quickly, he said.

The agency aims to ensure vaccine makers move forward the candidates with the most potential, he said.

What that will really mean from the FDA perspective is working with the various sponsors of the vaccines to most efficiently look at their preclinical data, understand as much as we can about the characteristics of these vaccines, (and) help people develop plans that are most efficient at understanding whether their candidates will get to the level of protection that would really warrant carrying them forward, because, frankly, vaccine candidates that have very low efficacy or not tremendous efficacy, in this particular case, could just distract from capacity for more robust candidates to come forward, he said.

Marks described the careful calculus of ensuring that any vaccine distributed is safe and effective while removing roadblocks to the fastest possible authorization and distribution.

We may not have the long-term data that we normally might like, so we may be putting real-world evidence into practice in this case by vaccinating relatively larger populations of individualsit may be individuals at higher risk for things like thisthen gathering data in the real world, he said.

Choosing which candidates to advance is an especially necessary and high-stakes effort in the face of a pandemic, Marks said.

My unique perspective on this is that its time to really mobilize as best we can in our animal modeling to try and compare things, to the extent that we can, and try and sort things out before we get to humans, knowing its never perfect to make that transition There is an opportunity cost to taking any candidate forward, and so you want to take your best candidates forward because, by definition, they will occupy capacity over one another, he said.

Esther Krofah, who heads the Milken Institutes FasterCures center, said drug companies appear to be operating with a similar timeline in mind, given some recent announcements about plans to ramp up manufacturing of their vaccine candidates in the event they prove safe and efficacious.

In recent weeks Johnson & Johnson (NYSE: JNJ) announced it had selected a lead vaccine candidate to advance against the novel coronavirus, and committed to boosting its manufacturing capacity to be able to make more than one billion doses of such a vaccine. The company anticipates human tests of its candidate to start at the latest by September, and said it expects batches could be ready for use under emergency guidelines in early 2021.

Thats a substantially accelerated timeframe in comparison to the typical vaccine development process, the company noted. Krofah says Milken is tracking 86 active vaccine projects, including six clinical trials; two dozen more are slated to enter the clinic in summer or early fall.

LJ Tan, chief strategy officer at the Immunization Action Coalition, emphasized the speed at which COVID-19 vaccine development is occurring compared to typical timelines for new vaccine innovation.

Tan previously spent about 16 years in leadership roles at the American Medical Association, most recently as director of medicine and public health and as director of infectious disease, immunology, and molecular medicine for more than a decade.

Traditional vaccine development, through all its phases, can take 10, 15, sometimes 20 years, and can cost at least $800 million dollars or even more, Tan said. When you build in all the costs to build the manufacturing facility, the equipment, the quality control that goes into this, the figure can go way over $1 billion to bring a vaccine from development all the way through to market.

Moderna (NASDAQ: MRNA), whose vaccine candidate was the first to start human testing in the US, said Thursday that it anticipated the start of a Phase 2 study this quarter, if safety data from the National Institutes of Health-led Phase 1 trial supports continuation. The Cambridge, MA-based biotech also announced that the US Biomedical Advanced Research and Development Authority (BARDA) had agreed to award it up to $483 million to fund the vaccines development through FDA review and ramp up its manufacturing to allow it to be produced at scale this year.

The company said it plans to add as many as 150 new employees by 2021.

Some vaccine candidates are being advanced in multiple geographies. This week Inovio Pharmaceuticals (NASDAQ: INO) announced a $6.9 million award from the Coalition for Epidemic Preparedness to move its vaccine into a Phase 1/2 trial in South Korea. Working with International Vaccine Institute and the Korea National Institute of Health, the trial will parallel Inovios ongoing Phase 1 in the US, which started April 6.

Remember, ultimately, were not talking about just vaccinating a few hundred thousand individuals, were taking about vaccinating a few hundred million people in this country alone and a few billion people globally, so one really would like to try to get it right to the extent they can, obviously working at a very rapid pace, Marks said.

Image: iStock/Nastco

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

View post:

COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market - Xconomy

Veterinary medicine at the forefront in the fight against COVID-19 – dvm360

Darryl / stock.adobe.com

Coronaviruses, so named for their knobby surface projections that create a crown-like appearance,1-3 were first identified in the 1930s but are thought to have originated more than 10,000 years ago.4,5 They and their associated illnesses have been observed in cattle, horses, cats, dogs, swine, rabbits, rodents and bats, among others.6,7

In humans, seven coronavirus strains have been identified, as have their bat and rodent reservoirs, and their intermediate hosts, including cattle, camels and civets.8-16 Most of these strains cause nothing more than the common cold in people, but threesevere acute respiratory syndrome (SARS),17 Middle East respiratory syndrome (MERS)18 and SARS-CoV-2have proven more daunting.

As the professionals with the most thorough understanding of One Health, veterinarians around the world have been working hard on COVID-19 diagnostic, prevention and treatment measures. Heres a look at some of the work being done.

At Cornell University College of Veterinary Medicine, a group of researchers have shunted their work to focus on SARS-CoV-2. Virology professor and coronavirus expert Gary Whittaker, PhD, who has done extensive research on MERS, is investigating the SARS-CoV- 2 spike protein and its mechanisms for fusing with the host cell.19 He hopes to apply his findings to drug and vaccine development. The team also includes investigators who are working on diagnostic tests for SARS-CoV-2.

Researchers at Louisiana State University School of Veterinary Medicine are working to develop a COVID-19 vaccine, slated to begin animal trials soon. The group, which includes investigators who study bovine coronaviruses, is collaborating with researchers at Tulane University, one of the first facilities to obtain samples of SARS-CoV-2 from the Centers for Disease Control and Prevention.

The coronavirus that afflicts cats and causes deadly feline infectious peritonitis (FIP) has long been a subject of research at the University of California, Davis, School of Veterinary Medicine. Investigators at the school have used an antiviral drug shown to block virus replication in monkeys and mice as a springboard for developing a protocol to treat FIP in cats experimentally infected with feline enteric coronavirus.20

"Its the virus-infected cells that are producing all of these nasty cytokines that are causing this inflammation, explains Niels Pedersen, DVM, PhD, who has been studying feline coronavirus for the past five decades, so if you can stop the replication cold in its tracks, you're going to immediately stop the cytokines from being produced."

Treatment has been largely successful in feline studies, which gives Pedersen hope for the nearly identical remdesivir, now in clinical trials for the treatment of SARS-CoV-2. If it can be done in cats, why can't it be done in humans?" he says.

The concept of drug repurposing might also be applied to the parasiticide ivermectin, an FDA-approved anti-parasitic agent for animals and humans that, in recent years, has been shown to have antiviral activity in vitro by interfering with virus replication.21-25 In vitro studies have demonstrated that ivermectin interferes with replication of many viruses, including human immunodeficiency virus 1,22 West Nile virus,23 dengue virus,22,24 Venezuelan encephalitis virus,25 simian virus,22,26 pseudorabies27 and influenza.21

A recent study,28 published in the journal Antiviral Research, demonstrates that ivermectin impedes SARS-CoV-2 in vitro.* Previous reports on similar coronaviruses describe the role of specific proteins in viral transport into the host nucleus, suggesting that ivermectins nuclear transport inhibitory activity may be effective against SARS-CoV-2.

Cells infected with SARS-CoV-2 were treated two hours post infection with a single dose of ivermectin at serial dilutions. At 24 hours, the addition of 5 M ivermectin produced a 99.8% reduction in cell-associated viral RNA, which increased to 99.98% at 48 hours; this equated to an approximately 5,000-fold reduction of viral RNA compared with control samples. No cell toxicity was observed at this concentration.

The studys Australian investigators, from Monash University and the Peter Doherty Institute for Infection and Immunity, hypothesize that ivermectin inhibits the IMP/1-mediated nuclear import of viral proteins, but they hope to confirm this mechanism in the case of SARS-CoV-2. The identification of the specific SARS-CoV-2 and/or host component(s) impacted is an important focus their future work.

This research sets the stage for development of an effective antiviral drug that, if given to patients early in infection, could reduce SARS-CoV-2 viral load, block disease progression and limit person-to-person transmission.

The answers to the COVID-19 pandemic will be shaped like medications and vaccines. And surely, they will be colored by extensive data established by the veterinary community.

*Editors note: The FDA has issued a public warning stating that people should not self-medicate with ivermectin in an effort to treat or prevent COVID-19. The warning reads, in part: FDA is concerned about the health of consumers who may self-medicate by taking ivermectin products intended for animals, thinking they can be a substitute for ivermectin intended for humans. People should never take animal drugs, as the FDA has only evaluated their safety and effectiveness in the particular animal species for which they are labeled. These animal drugs can cause serious harm in people. People should not take any form of ivermectin unless it has been prescribed to them by a licensed health care provider and is obtained through a legitimate source. For the full FDA letter, click here.

References

Visit link:

Veterinary medicine at the forefront in the fight against COVID-19 - dvm360

‘Open the doors for us.’ Indonesian scientists say government snubs offers to help fight coronavirus – Science Magazine

A woman hangs face masks out to dry before distributing them for free in a neighborhood in Tangerang, on the outskirts of Jakarta, on 9 April.

By Dyna Rochmyaningsih Apr. 18, 2020 , 3:35 PM

Sciences COVID-19 reporting is supported by the Pulitzer Center.

Scientists in Indonesia are exasperated at the countrys response to the COVID-19 pandemic, calling it shambolic and secretive, with a lack of coordination between the national and provincial governments. They also complain that officials have sometimes snubbed their efforts to help.

We have missed many opportunities in the past. What we need now is strong leadership to tackle the pandemic, says Nurul Nadia, a public health expert at the Center for Indonesias Strategic Development Initiatives. She and others say the country needs a clear national strategy for lockdowns and a dramatic increase in testing capacity if it is to control whatat least by official numbersis a comparatively small outbreak.

As of 18 April, Indonesia had 6248 confirmed COVID-19 cases, including 535 deaths. Nearly half of the known burden is in the capital, Jakarta, but all 34 provinces now report cases.

Epidemiologists say the number of actual cases is much higher. According to an estimate by Timothy Russel and colleagues at the London School of Hygiene & Tropical Medicine, published last month, only 5.4% of all symptomatic cases are reported in Indonesia, which means the country likely has well over 100,000 cases by now. One sign that COVID-19 is widespread is that mortality is spiking: Reuters reported last week that Jakarta had 4400 funerals in March, 40% more than in any other month since January 2018.

Thousands of migrant workers left Jakarta and returned to their hometowns in March, when the disease began to surge in the city, potentially spreading the virus around the country. Scientists have warned about another exodus just before 23 May, when Muslims celebrate Eid al-Fitr, a holiday marking the end of the Ramadan. A survey by the Indonesian Institute of Sciences (LIPI), in collaboration with academic researchers, found that 68% of respondents on Java hope to visit family then, some of them on other islands. There will be a surge of positive cases and deaths if we dont limit mobility soon, says Henry Surendra, an epidemiologist at the Eijkman-Oxford Clinical Research Unit in Jakarta. I am afraid that many areas will end up like Jakarta, Nadia says.

The Indonesian government, worried about paralyzing the economy, has long downplayed the danger of the pandemic. In early March, Achmad Yurianto, the director-general for disease control at Indonesias Ministry of Health, told Science he doesnt care what scientists say about the pandemic because they are not important if their information only creates panic. Health minister Terawan Agus Putranto suggested in February that prayer helped keep COVID-19 out of the country.

The Ministry of Health has authorized large-scale social restrictions or partial lockdowns for cities and provinces, providing they can show an escalating number of deaths and extensive local transmission. They must also demonstrate that theyre able to meet residents basic needs during the lockdown. But Nadia says many governors lack the epidemiological support to do such analyses. Should we wait for widespread infection and seeing people die first? she asks. If so, the concept of prevention wont work. So far, the health ministry has approved lockdown proposals from 10 cities, but compliance is low.

Meanwhile, testinga huge challenge in a country of more than 267 million, scattered over some 6000 islandshas been lagging. So far Indonesia has tested fewer than 40,000 people. Wide-scale testing may come too late for cities with a major outbreak, but if combined with isolation of patients and quarantining of their contacts, it could still help contain the virus in places where it has just arrived, says Panji Hadisoemarto, an epidemiologist at the University of Padjajaran in Bandung, West Java. Better late than never.

The government has assigned 132 referral hospitals around the country to take nose and throat swabs from suspected cases. But many lack the protective equipment to take samples safely. As a result, patients must sometimes be driven to hospitals many hours away. And the hospitals dont run the tests themselves; the samples are sent to one of 32 designated test labs, causing further delays.

Seeking to increase testing capacity, the Indonesian Biomedical Association (PBMI) has identified 106 laboratories in 25 provinces that meet the World Health Organizations technical requirements to test for COVID-19. Their findings, presented in early April, were quickly welcomed by Indonesias national COVID-19 Task Force, says Fenny Dwivanny, a molecular biologist at the Bandung Institute of Technology. That same day, health minister Terawan Agus Putranto issued a letter allowing qualified labs to do the tests.

There will be a surge of positive cases and deaths if we dont limit mobility soon.

But on 15 April, Yurianto told the press that the health ministry will authorize only 78 labs to scale up testing. We are dealing with a very deadly virus. We cant just do the PCR tests in any lab, he says.

Labs, even in the capital, also face a shortage of swabs, reagents, and protective gear, says Ahmad Utomo, a molecular biologist and senior advisor at PBMI. Utomo is encouraged, however, that the Ministry of State-Owned Enterprises is installing 18 PCR machines and 2 RNA extractorsrobots that can isolate viral RNA faster and more safely than humans canin hospitals run by the ministry in 12 provinces. (The ministry did not respond to a query from Science about details of its testing plans.

The Indonesian Young Scientists Forum (YSF) has also urged the health ministry to involve Indonesian scientists in sequencing the genomes of SARS-CoV-2 isolates from the country. So far, health ministry researchers have submitted only four partial sequences from Indonesia submitted to GISAID, the online database where scientists from around the world deposit their sequences. YSF scientists met officials at the ministry on 17 April to discuss collaboration, but no definitive decisions were taken, says Berry Juliandi, a biologist at Bogor Agricultural University and YSF spokesperson.

Despite their frustration, many scientists are eager to work with the government, says Utomo. Just show us the way and have a friendly attitude, he says. Open the doors for us.

Read the rest here:

'Open the doors for us.' Indonesian scientists say government snubs offers to help fight coronavirus - Science Magazine

The Painkiller We Really Need Might Come From Spider Venom – IFLScience

The world desperately needs painkillers that aren't addictive or heavy with damaging side effects. A strong candidate has been found in the venom of a tarantula known as a Chinese bird spider, and fortunately no further tarantula involvement is required.

Venoms are exceptionally chemically complex, usually involving hundreds of different molecules. With so many animals having adopted them for hunting or defense, they provide a biochemical bonanza, including one of the most prescribed drugs in the world captopril.

Dr Christina Schroeder of the University of Queensland is hunting for a replacement for opioids such as fentanyl and oxycontin in treating chronic pains like back pain. She told IFLScience she has a particular interest in neuropathic pain, which can be such a severe side effect of chemotherapy some people discontinue treatment.

Although opioids are effective in producing pain relief, they come with unwanted side-effects like nausea, constipation and the risk of addiction, placing a huge burden on society, Schroeder said in a statement.

Having identified the 1.7 sodium channel as an important chronic pain relief target, Schroeder went looking for molecules to fit. She told IFLScience another team had already identified Huwentoxin-IV in bird spider venom as a candidate.

Schroeder set about modifying Huwentoxin-IV to make it more specific, seeking something that would block the channel she needed but not affect the body's eight other sodium channels, minimizing the risk of side effects.

The process proved particularly complex. We normally talk about receptors and molecules as a lock and key, Schroeder told IFLScience, But in this case we had to look at the whole frame around the lock. The doorframe in this analogy is the lipid membrane that surrounds the channel, which influences molecular binding.

In the Journal of Biological Chemistry, Schroeder has announced that the modified Huwentoxin-IV proved successful at blocking pain in mouse trials without obvious side-effects.It's not clear why the spiders target this particular channel in their venom, but Schroeder says the diversity of molecules they inject hits their prey from many angles at once, minimizing capacity to run away or fight back.

Schroeder assured IFLScience that even if a drug from her work eventually hits the market, there will be no spider farms to terrorize our dreams. The molecule will either be synthesized inorganically or produced by genetically modified bacteria. Indeed, Schroeder added, I don't much like spiders. I have a postdoc who enjoys finding animals and milking them, allowing her to concentrate on the chemistry undisturbed.

More preclinical research is required before studies can begin on humans, so a product is probably 15 years away. People are starting to understand how hard it is to get a drug on the market quickly now we need a vaccine so much, she said.

See the article here:

The Painkiller We Really Need Might Come From Spider Venom - IFLScience

Coronavirus and the Heart – Harvard Medical School

This article is part of Harvard Medical Schoolscontinuing coverageof medicine, biomedical research, medical education and policy related to the SARS-CoV-2 pandemic and the disease COVID-19.

Lung injury and acute respiratory distress syndrome have taken center stage as the most dreaded complications of COVID-19, the disease caused by the new coronavirus, SARS-CoV-2. But heart damage has recently emerged as yet another grim outcome in the virus'srepertoire of possible complications.

Get more HM news

COVID-19 is a spectrum disease, spanning the gamut from barely symptomatic infection to critical illness. Reassuringly, for the large majority of individuals infected with the new coronavirus, the ailment remains in the mild-to-moderate range.

Yet, a number of those infected develop heart-related problems either out of the blue or as a complication of preexisting cardiac disease. A report from the early days of the epidemic described the extent of cardiac injury among 41 patients hospitalized with COVID-19 in Wuhan, China: Five, or 12 percent, had signs of cardiovascular damage. These patients had both elevated levels of cardiac troponina protein released in the blood by the injured heart muscleand abnormalities on electrocardiograms and heart ultrasounds. Since then, other reports have affirmed that cardiac injury can be part of coronavirus-induced harm. Moreover, some reports detail clinical scenarios in which patients initial symptoms were cardiovascular rather than respiratory in nature.

How does the new coronavirus stoke cardiac damage?

The ways in which the new coronavirus provokes cardiac injury are neither that new nor that surprising, according to Harvard Medical School physician-scientists Peter Libby and Paul Ridker. The part that remains unclear is whether SARS-CoV-2 is somehow more virulent toward the heart than other viruses.

Libby and Ridker, who are practicing cardiologists at Brigham and Womens, say COVID-19-related heart injury could occur in any several ways.

First, people with preexisting heart disease are at a greater risk for severe cardiovascular and respiratory complications from COVID-19. This is hardly a surprise. Research has shown that infection with the influenza virus poses a more severe threat for people with heart disease than those without cardiac problems. Research also shows that heart attacks can actually be brought on by respiratory infections such as the flu.

Second, people with previously undiagnosed heart disease may be presenting with previously silent cardiac symptoms unmasked by the viral infection. In people with existing heart-vessel blockages, infection, fever and inflammation can destabilize previously asymptomatic fatty plaques inside the heart vessels. Fever and inflammation also render the blood more prone to clotting, while also interfering with the bodys ability to dissolve clotsa one-two punch akin to throwing gasoline on smoldering embers.

Its like one big stress test for the heart, said Ridker, who is the Eugene Braunwald Professor of Medicine at Brigham and Womens Hospital.

Third, some people may experience heart damage that mimics heart attack injury even if their arteries lack the fatty, calcified flow-limiting blockages known to cause classic heart attacks. This scenario, called myocardial infarction type 2, can occur when the heart muscle is starved for oxygen, which in the case of COVID-19 may be triggered by a mismatch between oxygen supply and oxygen demand. Fever and inflammation accelerate heart rate and increase metabolic demands on many organs, including the heart. That stress is compounded if the lungs are infected and incapable of exchanging oxygen and carbon dioxide optimally. This impaired gas exchange can further diminish oxygen supply to the heart muscle.

Finally, there is a subset of people with COVID-19some of them previously healthy and with no underlying cardiac problemswho develop fulminant inflammation of the heart muscle as a result of the virus directly infecting the heart. This type of inflammation could lead to heart rhythm disturbances and cardiac muscle damage as well as interfere with the hearts ability to pump blood optimally.

The propensity of certain viruses to attack the heart muscle and cause viral myocarditis is well known, Libby said, adding that the most notorious viral offender has been the Coxsackie B virus. Nonetheless, a recent case report from Italy underscores the notion that the new coronavirus could also infect the heart and affect heart muscle function in healthy adults even after the acute phase of the infection has resolved and even in the absence of lung damage.

There are definitely some people who develop acute fulminant myocarditisin which the virus infects the heart muscle itself or the cells within the heartand causes a horrible inflammatory reaction, said Libby, who is also the Mallinckrodt Professor of Medicine at Brigham and Womens Hospital. This can be life threatening, and it can happen in people who don't have any preexisting risk factors.

Libby and Ridker, however, say this out-of-the-blue scenario in otherwise healthy individuals is likely rare relative to the overall number of people with COVID-19 who experience heart problems.

The frenemy within

For Ridker and Libby, who have studied the immune pathways of cardiovascular disease for decades, the cardiac involvement in COVID-19 is yet another striking example of the widespread effects of inflammation on multiple organs and systems.

Inflammation is a critical defense response during infection, but it has a dark side. Infections can set off a cascade of immune signals that affect various organs.

Libby and Ridker hypothesize that any infection in the bodya festering boil, an injured joint, a viruscan become a source of inflammation that activates the release of inflammatory proteins known as cytokines and calls up armies of white blood cells and other messenger molecules that, in an effort to fight the infection, disrupt normal processes. When these inflammatory molecules reach the welcoming soil of a fatty deposit in the blood vessel wallone that is already studded with resident inflammatory white blood cellsthe cytokines can boost the local inflammatory response and trigger a heart attack.

Our work has shown that cytokines can impinge on these cells in the plaque and push it through a round of further activation, Libby said.

The inflammatory chemicals released during infection can also induce the liver to ramp up the production of important proteins that defend the body from infection. These proteins, however, make the blood more prone to clotting, while also reducing the secretion of natural clot-dissolving substances. The tiny clots that may form can clog the small blood vessels in the heart and other organs, such as the kidneys, depriving them of oxygen and nutrients and setting the stage for the multisystem failure that can occur in acute infection.

Thus, immune-mediated injury to the heart and other organs could be collateral damage because of the bodys overwhelming systemic immune responsea condition known as cytokine storm, which is marked by the widespread release of cytokines that can cause cellular demise, tissue injury and organ damage.

COVID-19 and blood pressure medications

SARS-CoV-2 invades human cells by latching its spike protein onto the ACE2 receptor found on the surface of cells in the airways, lungs, heart, kidneys and blood vessels. The ACE2 protein is an important player in the renin-angiotensin-aldosterone system, which regulates blood vessel dilation and blood pressure. Two classes of drugs widely used to treat high blood pressure and heart diseaseACE inhibitors and angiotensin receptor blockersinteract with the ACE2 receptor. A possible concern related to COVID-19 stems from the notion that these blood pressure medications could increase the number of ACE2 receptors expressed on cells, possibly creating more molecular gates for the virus to enter. Some experts have wondered whether the use of such drugs could render people who take them more susceptible to infection. Conversely, others have postulated that the abundance of ACE2 receptors may enhance cardiovascular function, exercising a protective effect during infection.

The answer is far from clear, but a recent review suggests these medicines may play a dual role in COVID-19on the one hand, enhancing susceptibility to infection and, on the other, protecting the heart and ameliorating lung damage from the disease.

Libby and Ridker cautioned that patients who take such life-saving medications should stay on them or at least have a careful discussion with their cardiologists. This is because these drugs have clear and well-established benefits in hypertension and certain forms of heart disease, while their propensity to make humans more susceptible to SARS-CoV-2 remains speculative for the time being.

But what remains speculative today will crystalize in the weeks and months to come, Ridker and Libby said, because the science is moving forward rapidly, with new papers coming out daily and a growing pool of patients to draw observations from.

In 12 to 18 months we're going to have a great deal of information, but right now our job is to, number one, keep people from getting COVID-19 by strict adherence to now-familiar containment measures, Libby said. Then, we need to get people who get the disease through this acute phase.

The need for rigorous randomized trials done quickly and effectively is acute, they said. Until the evidence from these trials begins to coalesce, clinicians will have to navigate the uncharted territory of delivering cardiac care in the time of pandemic with caution but also with resolve.

We don't have the comfort of our usual databases, so we have to rely on our clinical skills and judgment. But we have to do so in all humility because often data dont bear out our logical preconceptions, Libby said. Yet, we must act.

RelatedEnding the Pandemic

See the original post here:

Coronavirus and the Heart - Harvard Medical School

Sudbury Accent: The best and worse case scenarios for COVID-19 – The Sudbury Star

Dr. Garry Ferroniis a bit of a legend. He is professor emeritus (retired) at the Northern Ontario School of Medicine and was a microbiology professor when I was a molecular biology student at Laurentian University. Most of my classmates and I were in awe of Ferroni.

His area of expertise is medical microbiology and infectious diseases. He has a PhD from the University of Waterloo and spent his career doing research and teaching at LU and NOSM.

At NOSM, he was the founding division head of medical sciences, as well as a professor, and he worked with colleagues in Sudbury and Thunder Bay to develop the infectious diseases curriculum for the medical program.

The Star reached out to Ferroni with some questions on COVID-19. Ever the helpful teacher, he was happy to oblige.

Q. In lay person terms, what is the novel coronavirus?

A. COVID-19 is caused by a virus officially named SARS-CoV-2, which stands for severe acute respiratory syndrome coronavirus 2. This virus is being referred to in the media as COVID-19 or novel coronavirus. It is the newest virus in a family of viruses called coronaviruses, so named because club-shaped protrusions from their surface give them a crown-like appearance.

Most of them infect animals such as bats, pigs and camels, but a few have managed to jump to humans.

In humans, they tend to cause mild upper respiratory tract infections diagnosed as the common cold. The exceptions are the coronaviruses that cause SARS, Middle East Respiratory Syndrome (MERS) and COVID-19. These coronaviruses are more adept at invading the lower respiratory tract where they can cause a very severe pneumonia.

Dr. Garry Ferroni is a retired professor from NOSM and Laurentian University. He taught microbiology and infectious diseases. In fact, he helped establish the curriculum for the medical school.supplied photo

Q. Do we know how the virus was transmitted from animal to human? How is it transmitted from person to person?

A. The assumption is the COVID-19 virus was transmitted from animal to human, and the animal often mentioned is the bat. There are some who suggest that animals called pangolins might be an intermediary host, which means the virus moved from an unknown animal to pangolins and then to humans.

The possibility that an exotic animal market in Wuhan, China, provided the opportunity for animal to human transmission has not been proven. At this point, the origin of the virus just isnt known. Studies of the sequence of the viruss genetic material (genome) relative to other coronavirus genomes do indicate the COVID-19 virus arose naturally as opposed to being created in a research laboratory.

It is likely that infected persons transmit the virus to other persons via respiratory droplets in their coughs and sneezes (such droplets might even be discharged by talking and deep breathing) and by direct contact, such as hand-shaking and hugging. It follows that infected persons would contaminate surfaces and objects via droplets and direct contact. If we touch or handle these and then touch our faces, we can introduce the virus into our bodies, the entry sites being the mouth, nose and eyes. Knowing how infectious agents are transmitted allows us to protect ourselves and our contacts.

Registered nurses Karen Hatton, left, and Theresa Murray stand inside a shelter associated with the drive-through option for coronavirus testing on Walford Road.Jim Moodie/Sudbury Star

Q. How long does the virus live on different surfaces, such as plastic, metal, produce?

A. Viruses can survive on surfaces for a limited period of time, but they cannot multiply. They must invade the cells of an appropriate organism to multiply. Not surprisingly, there is not a lot of information on the survival of the COVID-19 virus when it is outside of the human host.

Studies at or supported by the National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention, both of which are American institutions, have shown survival in aerosols for up to a few hours; on copper for up to a few hours; on cardboard for up to one day; and on plastic and stainless steel for up to a few days.

Concerning produce, as other pathogens can be found transiently on fruits and vegetables as a result of contamination, we should expect this to be true for COVID-19 as well, and we should wash and rinse our produce thoroughly. This means there should be no more tasting of grapes or cherries in the supermarket.

Q. There is lots of (mis-) information online about ways to kill the virus, particularly around heat and the use of saunas. Can you dispel some of those myths?

A. With a few exceptions possibly, cold temperatures do not kill viruses. Heat, on the other hand, definitely kills viruses, but the minimum temperature and exposure time to accomplish this vary from virus to virus.

Generally, 60-minute exposures to temperatures above 60 C kill most viruses, as would shorter exposures to higher temperatures. Nevertheless, using these moderate temperatures to try to eliminate viruses is not very practical.

Viruses are killed by a variety of disinfectants and by hand sanitizers that contain at least 60 per cent alcohol. In the process of proper hand-washing, employing soap and warm water, viruses are physically removed from the skin. Coronaviruses are actually killed because soap removes their membranous envelope that allows them to attach to host cells to initiate infection.

Q. Why and how does the virus make people sick (in lay terms)?

A. COVID-19 is a severe acute infection of the respiratory tract. A likely progression of the disease is as follows:

Upon entering the body, the virus establishes itself in the upper respiratory tract (nose and throat).

Around five to six days after exposure, the first symptoms occur, one or more of fever, dry cough, fatigue, aching muscles, sore throat and nasal congestion. In more serious cases the virus moves into the lower respiratory tract (the lungs) to cause a pneumonia that is indicated by shortness of breath.

The development of the disease is due to the ability of the virus to infect and kill cells that line the respiratory tract, including the air sacs in the lungs, and to an exaggerated response by the immune system that causes extreme inflammation in the lungs. This affects our ability to breathe.

Age and overall health are factors in the severity of the disease. Older adults and those with chronic diseases of the lungs and heart, for example, are most likely to experience serious disease, whereas healthy children are least likely.

An inspirational message is displayed in a window of a home in Sudbury on April 16.John Lappa/Sudbury Star

Q. What about treatment and prevention?

A. Treatment of a viral disease like COVID-19 requires administering an effective antiviral agent or administering antibodies that eliminate the virus. Antibodies are proteins produced by the immune system in response to infection, and for some diseases, they can be made available for therapeutic use.

Currently, neither type of therapy is available, but research and trials are in progress. The major preventative would be a vaccine and this is being pursued.

Q. Does this virus show much capacity for mutation? Should we be concerned about mutation?

A. The genome of a virus can be altered by a change in the base sequence, a process called mutation. It can also be altered by a process called genetic recombination, in which a second virus contributes some of its genome to another genome. Genetic recombination can happen if the two different viruses infect a host cell at the same time.

Mutations tend to cause minor changes in the characteristics of the virus, whereas genetic recombination can result in major changes. It is these major changes that can produce a new strain of the virus capable of causing a pandemic, as there is no immunity to the new strain. Given that coronaviruses have been shown to mutate and to undergo genetic recombination, and to move from one animal species to another, we should expect the same of the COVID-19 virus. This means, of course, that a disease similar to COVID-19 could emerge in the future.

Q. Once youve been sick, are you immune to the virus?

A. It is a reasonable assumption that individuals who have had the disease will have a substantial period of immunity, if not life-long immunity, to subsequent exposure to the same strain of the virus. Moreover, immunity as a result of having had a disease is superior to that acquired by any immunization procedure (vaccine), which should be true for COVID-19 as well.

Q. Can you predict how this virus will travel through the human population? Do you foresee a second/third/fourth wave of sickness?

A. It is difficult to predict virus movement through the population, but if we look at what has happened thus far in our province and in countries further into the pandemic we see that: older adults and individuals with certain chronic conditions get seriously ill; certain sites in a community, for example, long-term care facilities, can have high densities of infection; individuals who provide essential services are exposure-prone; and hospitals can be overwhelmed with patients needing intensive care.

Past influenza pandemics tell us there can be more than one wave of illness, each separated by a few months. Because the reasons for a second or even third wave are not always known in advance, it is difficult to predict waves. It is much easier to account for them after the fact.

Q. What are the best- and worst-case scenarios?

A The best-case scenario would be if our preventive measures had a major positive impact and terminated this outbreak within a few months. For this scenario, as for some others, there would be the issue of individuals at highest risk and without immunity emerging from isolation into a population where some might still be harboring COVID-19. The development of a vaccine or effective anti-viral medication would eliminate this as an issue.

The worst-case scenario would be to experience for an extended period of time what is currently happening in Italy, Spain and the USA.

Q. There has been media attention on the need to strip and change clothes when you come home. Is this necessary? What other measures, besides washing hands, maintaining distance and stifling coughs, should we be putting into practice?

A To protect ourselves, family members and others, it is important to adopt effective procedures and behaviours. As respiratory droplets discharged by infected persons travel in the air for a metre or so, maintain a safe space of two metres. Cough and sneeze into the bent arm or into a tissue. Avoid touching ones face to prevent introducing the virus into your body. Wash hands properly with soap and warm water, frequently and at critical times. Sanitize hands at critical times with sanitizer containing at least 60 per cent alcohol.

If you decide to wear a mask when you are in public, sanitize your hands before putting the mask on and just before and just after taking the mask off, and be aware the mask might collect infectious droplets. Do not use masks designed for health care workers because of their limited supply.

We should be aware that clothing can become contaminated if the two-metre barrier is broken and by contact with or transfer from surfaces and objects. Individuals should assess their own probability of exposure and that of their children, and decide if changing clothes is necessary.

The Public Health Sudbury and Districts website (phsd.ca) should be visited frequently and the recommendations for isolation and in-person socializing followed.

sud.editorial@sunmedia.caTwitter: @SudburyStar

Go here to read the rest:

Sudbury Accent: The best and worse case scenarios for COVID-19 - The Sudbury Star

‘Smart toilet’ recognizes users and checks for signs of disease – Medical News Today

A team at Stanford Medicine has developed gadgets that can be fitted in an ordinary toilet to screen urine and feces and upload the encrypted health data. The technology may be particularly useful for monitoring individuals at high risk of developing particular illnesses.

Many people will be uncomfortable with the idea of cameras and sensors in their toilet. It may seem like an unthinkable intrusion into what is perhaps the most private of all activities.

But a team of developers at Stanford Medicine in Stanford, CA, believe the clinical benefits of their smart toilet could be far-reaching.

They are also confident that their toilet can safeguard the privacy of users.

Technologies that continually monitor a persons health play a growing role in healthcare.

Existing devices include smartwatches for collecting data, such as heart rate, and wearable blood pressure monitors. A skin patch is in development that tracks movement, heart rate, and breathing.

The thing about a smart toilet, though, is that unlike wearables, you cant take it off, says Prof. Sanjiv Gambhir, chair of radiology at Stanford Medicine. Everyone uses the bathroom theres really no avoiding it and that enhances its value as a disease-detecting device.

Prof. Gambhir believes the smart toilet may be particularly useful for monitoring people at high risk of conditions, such as prostate cancer, irritable bowel syndrome (IBS), and kidney failure, due to their genetic predispositions, for example.

His team developed a suite of gadgets that a person can fit in the bowl of an ordinary toilet. Its sort of like buying a bidet add-on that can be mounted right into your existing toilet, he says. And like a bidet, it has little extensions that carry out different purposes.

In a pilot study, 21 volunteers tested the device over several months.

The smart toilet is the perfect way to harness a source of data thats typically ignored and the user doesnt have to do anything differently.

Prof. Sanjiv Gambhir

A motion sensor activates the smart toilet to start capturing video data, which are then digitally analyzed.

One of the smart toilets algorithms can detect abnormal urine flow rate, stream time, and volume, which could be useful for flagging prostate problems in men, for example.

Another gauges the consistency of fecal matter from the images and classifies it according to the Bristol stool chart. This is a standardized system used by clinicians worldwide to diagnose problems such as constipation, gut inflammation, and a lack of dietary fiber.

The smart toilets software can also identify color changes in urine using urinalysis strips (dipstick tests). It can detect 10 different markers, including the number of white blood cells and the levels of specific proteins in the urine. These biomarkers can provide early warnings of diseases, such as kidney infections and bladder cancer.

According to an article describing the technology in Nature Biomedical Engineering, the toilets abilities are comparable to the performance of trained medical personnel.

Encrypted data from the toilet upload to a secure cloud server. In the future, this information could integrate with a healthcare providers record-keeping system for easy access by the individuals doctor.

The Stanford team envisages an app sending a text alert to the healthcare team if the device detects an urgent issue, such as blood in someones urine.

Identifying who is using the toilet will be critical in a household of several people.

The whole point is to provide precise, individualized health feedback, so we needed to make sure the toilet could discern between users, Prof. Gambhir said. To do so, we made a flush lever that reads fingerprints.

However, in case someone uses the toilet and another flushes it, or if the toilet has an auto-flush system, a camera captures what the article calls the distinctive features of their anoderm [skin tissue lining of the anus].

We know it seems weird, but as it turns out, your anal print is unique, says Prof. Gambhir.

The recognition system is fully automatic, which means that no human will see the scans.

Despite the teams best efforts to ensure user privacy and data confidentiality, the smart toilet may prove a hard sell.

A survey conducted by the researchers of 300 prospective users revealed that only 15% described themselves as very comfortable with the concept.

The researchers plans include recruiting more volunteers to test the toilet and individualizing the available tests. A patient with diabetes might want glucose levels in their urine checked, for example.

In addition to urine tests, the team would also like to build into their toilet the ability to carry out molecular analysis of stool samples.

Thats a bit trickier, but were working toward it, says Prof. Gambhir.

If successful, one advantage for the squeamish will be that they no longer have to collect their own stool samples and take them to a clinic for testing.

Go here to see the original:

'Smart toilet' recognizes users and checks for signs of disease - Medical News Today

Research in most university labs moved from bench to internet – Washington University in St. Louis Newsroom

Visit the News Hub

Some labs remain active, with focus switched to COVID-19

A School of Medicine lab member packs up items in a lab in the Couch Biomedical Research Building. Research in most of the universities' labs has been ramped down due to the COVID-19 pandemic.

When Washington University Vice Chancellor for Research Jennifer K. Lodge, PhD, first sounded the alarm about the disruptive impact COVID-19 likely would have on labs across the university, the research community heeded her warning, taking steps to shut down lab work and move as much as possible online.

Those in position to do so began pivoting their research to the novel coronavirus that has caused an unprecedented shutdown of public life across the globe. In a very short span of time, the universitys scientific community has responded to the pandemic with extraordinary research collaborations, all the while finding new ways to keep faculty, staff and students connected as they shift work out of the lab and into cyberspace.

For all of us who are passionate about our research, we know that ramping down and pausing our work is very difficult, said Lodge, a professor of molecular microbiology who also serves as associate dean of research for the School of Medicine. At the same time, this unusual situation may provide a rare opportunity for researchers to slow down our typically fast pace and think deeply about our science and connect with colleagues in ways we havent before.

Scientific research is a complex endeavor, and figuring out how to slow or stop research that might involve living cells or mice is not a simple task. The Office of the Vice Chancellor for Research is constantly updating its coronavirus information website, Guidance for Researchers on COVID-19, and recommends that investigators frequently refresh the site to check for updates on the fast-changing advice and resources available to researchers, including updates from funding agencies, such as the National Institutes of Health (NIH). The office also has held virtual town hall meetings via Zoom to keep researchers up to date.

Sarah K. England, PhD, the Alan A. and Edith L. Wolff Professor of Medicine, has moved much of her lab online and set up a small, rotating group of people to take care of lab tasks that need to continue, even during a shutdown. Englands lab focuses on studies of the uterus and factors that might lead to preterm birth.

We immediately made sure everyone has access to their data online, through Box, so that we all can work remotely, England said. Fortunately, quite a few people in my lab can focus on writing or new project planning. We still have a skeleton crew going into the lab to check on things we absolutely must check on. We set up an online calendar showing when people are going in so theres no overlap and we can maintain safe physical distancing. Its been helpful to have somebody there because we also were able to collect PPE to donate to coronavirus-focused clinical efforts.

Farshid Guilak, PhD, a professor of orthopedic surgery, described similar steps taken in his lab. Many labs, including his and Englands, are trying to maintain special colonies of mice. Even though active research may have stopped, it is important to continue caring for these groups of mice with special genetics and other characteristics that make them unique, so that work can ramp up again quickly when researchers are able to return to the lab. As a backup, researchers also have cryopreserved embryos of such specialized mice to ensure their survival.

Fortunately, at this point, we are able to continue to feed our mice their special diets, Guilak said. We study models of obesity and how that might increase the risk of developing arthritis. Were doing our best to minimize the impact of not having our typical access to the mice.

This lab in the Couch Biomedical Research Building normally would be bustling with activity but has been quieted due to a research rampdown ordered in response to the COVID-19 pandemic.

The School of Medicines COVID-19 task force orchestrating research into the novel coronavirus is led by Jeffrey Milbrandt, MD, PhD, the James S. McDonnell Professor and head of the Department of Genetics; William G. Powderly, MD, the J. William Campbell Professor of Medicine and director of the Institute for Clinical and Translational Sciences (ICTS); and Sean Whelan, PhD, the Marvin A. Brennecke Distinguished Professor and head of the Department of Molecular Microbiology. A major focus of this work includes creating mouse models of COVID-19 infection and vaccine development.

In addition, researchers who study other viruses, lung infections or have other related expertise are turning their labs resources to the novel coronavirus. Shabaana Khader, PhD, a professor of molecular microbiology, studies tuberculosis (TB); and Jacco Boon, PhD, an associate professor of medicine, is focused on influenza viruses. Both are uniquely positioned to trade research into one dangerous lung infection for another.

Because we study other types of respiratory viruses, our lab is ideally equipped to conduct basic research on the COVID-19 virus, Boon said. We can grow the virus in our facility and, once we have animal models, we can start testing new compounds and antibodies for potential treatments. One challenge is that mice dont have the lung receptor that this virus targets to infect human lungs. One solution could be to genetically modify mice to express the human lung receptor.

Khader studies the lungs immune response to tuberculosis (TB) infection. Her team could, potentially, help shed light on how the immune system in the lungs reacts to coronavirus infection. As part of her TB research, Khader works with a collaborator at the Texas Biomedical Research Institute, Deepak Kaushal, PhD. Kaushal studies TB infection in macaques, nonhuman primates that have the lung receptor for COVID-19 infection.

When we receive lung samples from his group, we will be using single cell technology to study the lung immunology of this disease, Khader said. We will be able to look at the immune response over time and how it might change from the first few days of infection to longer time points. So, my lab is shutting down our TB operations and ramping up COVID-19 work.

Even investigators whose research might seem to have little to do with respiratory viruses are exploring aspects of COVID-19, such as investigating ways the pandemic is influencing childhood development. Deanna M. Barch, PhD, the Gregory P. Couch Professor and head of the Department of Psychological & Brain Sciences, co-leads the Adolescent Brain and Cognitive Development Study, a national study with multiple clinical sites involving a broad sample of children across the country. As much as possible, the studys assessments have been moved online.

We are adding assessments that directly address COVID-19 in terms of its impacts on families and kids, Barch said. We would like to understand what factors may predict resilience in this stressful situation and how that might impact brain development over time.

Lori A. Setton, PhD, the Lucy and Stanley Lopata Distinguished Professor and chair of the Department of Biomedical Engineering, said that several professors in her department also have pivoted their research to COVID-19, including studying the heart arrhythmia that some patients experience.

She also talked about supporting faculty members who are teaching online for the first time while ramping down work in their labs.

I held drop-in coffee hours on Zoom, so faculty members could tell me what they needed to help with the transition, Setton said. Many lab groups are holding virtual happy hours to have more casual discussions about their transitions to remote work and their research strategies moving forward. There are a lot of humorous and uplifting stories about these transitions that it has helped to share.

Setton, Khader, England, Guilak and others also talked about the importance of maintaining social ties during this time of social distancing, and providing support for their lab members physical and mental well-being.

Labs are little communities, and many of our trainees are far from home, so were concerned about everyones mental health, Guilak said. Were trying to check in with everybody on a regular basis. Were continuing our regular lab meetings online and then having smaller group meetings every week. Several of our trainees have started their own journal clubs. All of this is over Zoom or otherwise online, but its important to maintain the connections.

Added England: Many of our people have young children at home, and were trying to make sure everyone has the time and ability to adjust to the challenges of working from home for a while.

Many labs and groups around campus have found ways to use Slack to stay connected. Guilak said his lab has a Slack channel called Positivity, where they share photos of kids and pets and trade recipes and cooking tips.

I am inspired by the response of the Washington University community to this unprecedented situation, Lodge said. Thank you to those who have switched their work to COVID-19. And thank you to everyone who has taken steps to ramp down all other research in their labs and work remotely to keep as many people off campus as possible. Together, we are doing our best to bend the curve and help protect our clinical colleagues on the front lines fighting this virus.

Postdoctoral researchers Brett Case, PhD, (left) and Adam Bailey, MD, PhD, wear full personal protective equipment to study the COVID-19 virus. Washington University School of Medicine in St. Louis physicians and researchers are preparing for COVID-19 cases and working on drugs and vaccines to fight the disease.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Go here to read the rest:

Research in most university labs moved from bench to internet - Washington University in St. Louis Newsroom

‘I focus on low-cost tech to fight infectious diseases’ – Business Mirror

A lot has been said and written about the Philippine-made test kitthe first in the countryfor the 2019 coronavirus disease (Covid-19).

As soon as it was announced in March that a Covid-19 test kit is being developed and manufactured in the country, all the news media platforms, columns and talk shows have been awash with stories on the subject. Its been the talk of the town.

Interviews with its creatorled by the multi-awarded Dr. Raul V. Desturahave been held left and right, seeking the story behind the diagnostic system that will help stem the spread of the virus in the country, and proud that it was made in the Philippines, plus being cheaper at P1,300 than the imported P8,000.

Actually the kit is already being used now at the Philippine General Hospital (PGH) and other major hospitals around the country that are handling Covid-19 cases after the Food and Drug Administration Philippines(FDA) approved its commercial use on April 3.

The test kit was developed in collaboration with the University of the Philippines-National Institutes of Health (UP-NIH), and funded by the Department of Science and Technology (DOST). It is manufactured by Manila HealthTek that was also supported by the DOST.

It was a just-in-time scenario for the Philippines when it badly needed test kits for Covid-19 cases.

It was a much-awaited result of research and development, which was conducted immediately when the coronavirus pandemic startled the whole world in January 2020. This completely upholds the DOST of the mantra R&D making change happen.

Despite Desturas being busy attending to interviews, they were mainly about his research on the test kit, and rarely about himself.

Who is this scientist behind the Covid-19 test kit?

As a clinician-scientist, I continuously try to narrow down the gap between basic science, medical science, biotechnology and community service by forging strong collaboration among disciplines to reach a focused goal, Destura said as quoted by the NIH UPM web site.

My research bench to community approach is ultimately geared toward developing low-cost technologies for the control of infectious diseases in the Philippines and the generation of new knowledge to find sustainable and equitable solutions to disease of poverty, added Destura, the vice president and chairman of the Division of Medical Sciences of the National Research Council of the Philippines (NRCP).

A Presidential Lingkod Bayan 2019 Awardee, Destura is a known scientist and molecular microbiologist who is also recognized for developing local and less costly diagnostic kits for rapid detection of the most dreaded infectious diseases such as dengue, hepatitis and tuberculosis.

Notable of these is the Biotek-M, a rapid test kit for dengue that is projected to be more affordable among average Filipino families that may not be able to afford the more expensive polymerase chain reaction technology.

This new technology is hoped to advance the diagnostic capability of the hospitals for better management of the dengue disease. Biotek-M is currently being rolled out to three government hospitals.

Actually the Covid-19 test kit was based on the Biotek-M technology.

Desturas versatility is exhibited by the establishment of two world-class molecular biology laboratoriesthe Molecular Biology and Biotechnology Research Laboratory at the UP NIH and the Clinical Molecular Diagnostic Laboratory of the Medical Cityunder his leadership.

He is also a recipient of several prestigious national and international awards for his innovative research and leadership in research and clinical molecular biology.

Among the awards are the Gold Medal from the International Exhibition of Inventions of Geneva (Salon International Des Inventions Geneve), Geneva, Switzerland in April 2018; International Training and Research in Emerging Infectious Diseases Research Fellowship Award from the Center for Global Health Division of Infectious Disease and International Health, University of Virginia.

The Bill and Melinda Gates Travel Scholarship for 2005 Keystone Symposia; Outstanding Young Scientist of the Philippines in 2008; University of the Philippiness Research Productivity Award in 2011; The Outstanding Young Men of the Philippines in 2011; Gawad Agham 2015.

Outstanding Alumni in Microbiology of the University of Santo Tomas; 2015 Outstanding Alumni in Medicine of the De La Salle University; and the prestigious 2015 Dr. Jose Rizal Memorial Award in Research given by the Philippine Medical Association.

At the NRCP, Destura was named the 2015 Dr. Eusebio Y. Garcia awardee. The award is given annually to Filipino scientists in recognition of their outstanding research contributions in the fields of Molecular Biology and Molecular Pathology.

The award was founded by Dr. Eusebio Y. Garcia in 1985 to encourage more researchers to venture into this field and also to recognize the ground breaking researches made by the Filipinos in the said field.

In June 2018, immunization became a hot topic in the country because of the Dengvaxia scare. Amid the controversy, the NRCP made a categorical pronouncement on the importance of vaccines.

The NRCP statement, crafted by Destura, stated that scientific evidence has clearly demonstrated that vaccines have dramatically eradicated small pox and polio and have greatly reduced child mortality in the Philippines and in many parts of the world. The NRCP stands by the government efforts to sustain its immunization programs as we strongly urge the public to pay attention to the knowledge claim of scientists on the beneficial effects of immunization.

On March 7, while in the midst of isolation for his research work on the Covid-19 test kit, NRCP President Dr. Ramon A. Razal consulted Destura when the Department of Health raised Red Code Alert on Covid-19.

Upon Desturas expert advise and with the NRCP Governing Board approval, Razal postponed the NRCPs biggest annual event, the Scientific Conference and 87th General Assembly in Manila on March 9. The conference has an anticipated 1,200 participants from all over the country.

The decision became the Councils contribution to the national efforts to prevent the risk of further local or community transmission of Covid-19.

Destura studied Medicine at the De La Salle University Health Sciences in 1996, and went to pursue training and research fellowship in Infectious Disease at the UP-PGH from years 20012003.

He went to University of Virginia, US, for higher learning and international training in Emerging Infectious Diseases. Maria Elena A. Talingdan, S&T Media Service

Read the original here:

'I focus on low-cost tech to fight infectious diseases' - Business Mirror

Coronavirus in Ireland: What we know so far – The Irish Times

How is Ireland doing in the fight to slow the spread of Covid-19?

After more than two weeks of lockdown with wide ranging restrictions limiting commercial and social life, the battle rages on and there are no definitive signs that a peak has been reached. The country is at a delicate and critical point in its response to the coronavirus outbreak, according to Liz Canavan the assistant general secretary at the Department of the Taoiseach. Many people have fallen ill and too many have died and while there is some optimism that the Republic may not be hit as hard by Covid-19 as Italy, Spain and the UK, it is still too early to say what may happen in the weeks ahead.

What are the numbers?

On Tuesday, April 14th, 41 more people were reported to have died from coronavirus in the Republic taking the total number of fatalities to 406 while the number of known cases reached 11,479. Modelling data used by the National Public Health Emergency Team shows the daily growth rate has fallen from 33 per cent in the early stages of the outbreak to 9 per cent this week.

What is happening in Northern Ireland?

Ten more coronavirus-related deaths were announced in Northern Ireland on Tuesday, bringing the total number of fatalities to 134. On the same day a total of 1,967 cases had been identified in the North.

How is the Republic doing when it comes to testing?

Testing and contact tracing in real time between 24 and 48 hours is needed to fully contain the disease, experts have said. Minister for Health Simon Harris has said the mantra is to test, test, test. There have been widely reported shortages of testing kits and lab supplies and the waiting times for results, according to the Department of Health, was about seven to 10 days. But things have improved.

HSE chief executive Paul Reid said a backlog in testing had been reduced from a high point of about 35,000 people waiting for results to some 11,000. He told a briefing in Dublin on Tuesday that 25 laboratories were now being used to examine Covid-19 tests, including 20 in hospitals, the national lab in UCD, a Department of Agriculture facility and in Germany. Mr Reid said nearly 8,000 tests were completed on Saturday. That backlog will continue to be reduced and will be reduced completely by the end of this week, he said.

How does that compare with elsewhere in the world?

Mr Reid, has said that Ireland is a top-tier country although that claim has been disputed by some. Dr Sean LEstrange, a social scientist in UCD, has conducted a comparative analysis of reported testing figures. It is difficult to support the claim that Irelands testing practice for Covid-19 is in the top tier in the world, he wrote this week. Ireland is not doing badly and it is certainly not amongst the worst in the world by any stretch of the imagination. Yet compared with other similar-sized and resourced states in the European context, its performance is decidedly middling, he wrote.

How important is the testing?

If you have symptoms, it may not matter all that much. If you become sick enough to be hospitalised, you will get a fast-track result but if not, you stay at home and self-isolate until the symptoms lift. The reason testing really matters is that it is a key part of relaxing restrictions. Building a system that can turn around results, and fast, is key, according to chief medical officer Dr Tony Holohan. We need to have a contact-tracing capacity and testing capacity to give us real-time in other words same-day or following-day results, he said.

Speaking of testing, will the Leaving and Junior Certificate exams go ahead?

Last week, Taoiseach Leo Varadkar said the State exams would go ahead by hook or by crook and so they will or at least one set will. It was confirmed on Friday that the Leaving Cert would take place in late July or August. The Junior Cert, meanwhile, is set to be replaced by school-based exams which will run early in the new school year.

The changes mean tens of thousands of students who are due to progress to third level and further education are likely to commence their courses much later than originally planned. Deadlines for students to complete practicals and project work in a number of subjects such as history, geography and home economics will also be extended until late July. Students had been given a deadline of May 15th to complete this work. While the move will bring much-needed clarity to students over contingency plans for the Leaving Cert, it is likely to be a major disappointment for many students who now face an extended summer preparing for the exams.

Movement is still seriously restricted, what powers do garda have to enforce this?

At the beginning of last week, Mr Harris signed regulations granting powers of enforcement to garda. The powers were passed by the Oireachtas in late March but became active only with the Ministers signature. The regulations are based on the guidelines issued by the Government two weeks ago and anyone exercising more than 2km from their home or with people from outside their household will be in breach of the law. Anyone travelling beyond 2km for non-essential reasons will also be in breach. An offence will be committed only if a person refuses a direction from a garda to comply with the regulations. It is not the breaching of regulations that is illegal, but disobeying the gardas instructions once caught.

Will there be many arrests?

Front-line garda have been instructed to use a four-step graduated policing response in the days ahead and should give members of the public every opportunity to comply with the regulations.

Enforcement will be a last resort and only when all other avenues have been exhausted in most cases, an internal Garda document says. Before resorting to arrest, garda must go through the four-step escalation process termed Engage, Explain, Encourage, Enforce. Engage involves asking people their name and address, reason for travel and if they are aware of the restrictions. Garda may arrest anyone who refuses to give their name and address. If required they then move on to the explain stage, which involves highlighting the risks of breaking the rules. They must then encourage those in breach to stay at home to save lives. The final step, enforce, involves using Garda powers to discourage further non-compliance. This should be done only when necessary and proportionate.

How was the bank holiday weekend?

There was a very high level of compliance with restrictions on non-essential travel over the bank holiday weekend, according to Ms Canavan. A major policing operation was put in place over the Easter bank holiday with checkpoints across the country to ensure people complied with public health guidelines, over fears people would travel to holiday homes due to the fine weather.

And were there many arrests?

Garda made seven arrests over the long weekend under the new legislation. An Garda Sochna said these arrests were made when people repeatedly refused to comply with directions to abide by the movement restrictions which prohibit unnecessary travel and exercise further than 2km from the home. In addition there were 144 incidents where garda enforcing the coronavirus restrictions instead made arrests under other, long-standing legislation. These incidents included arrests for public order breaches, assault, road traffic offences and drug offences. The arrests were made at house parties and street gatherings and where garda found people engaged in non-essential travel.

If I got Covid-19 can I get it again?

No one knows for certain what level of immunity those who have had and then recovered from the illness will have. We simply dont know yet what it takes to be effectively protected from this infection, Dawn Bowdish, a professor of pathology and molecular medicine in Ontario told Scientific American this week.

What we do know is that immunity to other coronaviruses, including the common cold, can start declining within weeks of infection.

Within weeks? That doesnt sound good?

No, but studies of Sars-CoV the virus that causes Sars, which shares a lot of the same elements as Covid-19 suggest that immunity peaks at around four months and offers protection for roughly two to three years. That would give time for a vaccine to be developed without those with the Covid-19 antibodies becoming reinfected.

Are more young people dying from the illness than expected?

The early narrative was that Covid-19 was an illness that largely spared young and healthy people but as it has spread across the world, it has shown itself to be more indiscriminate than many health experts initially thought. As it stands in Ireland more than 90 per cent of the victims have been over 65. While older people and those with pre-existing conditions are most at risk, it has occasionally hit young and apparently fit people including healthcare workers exposed to those with the virus. The youngest person to die so far was aged 30, the oldest was 105 years.

Why is that?

Sometimes previously undiagnosed conditions are later revealed and sometimes there are no such explanations.

What are the scientists saying?

There have been many theories circulating in medical and scientific circles. There is a school of thought which suggests that a huge dose may hit people much harder than smaller doses while another school of thought points to genetic susceptibility with some people more vulnerable to the virus than others, irrespective of their age. It is very possible that some of us could have a particular genetic make-up that makes it more likely that we will respond badly to an infection with this coronavirus, virologist Michael Skinner at Imperial College London told the Guardian newspaper this week.

A person with a high viral load has more virus particles than one with a low load, said virologist Alison Sinclair at Sussex university. We do not yet know what impact viral load has on the symptoms of a person infected with Covid-19. Whether there is a link between a high viral load and worse outcomes is going to be important to find out.

What has been happening in nursing homes in Ireland?

The number of coronavirus infection clusters in nursing homes around the country has reached 149, according to the latest detailed figures on coronavirus cases released by State officials. Nursing homes now account for one-third of the clusters of infection across the country. This is incredibly serious not only because of the vulnerability of those in such care settings. It has become clear that Covid-19 has virus loads which are three times what might be found with other respiratory viruses such as flu, including in older patients, who are more contagious than expected.

How significant is that?

It is very significant. These are the highest viral loads for any virus I know, Prof Marc Van Ranst at the Rega Institute for Medical Research in Leuven, Belgium, said this week. He said he was astonished at the number of the germs he saw from patient throat samples in his lab. Especially surprising, he said, was that elderly people harbour prodigious quantities of virus.

Not many elderly [people] are going to transmit the influenza virus to someone else. They get infected, but are not infecting others, said Prof Van Ranst not so for Covid-19. When I look at the viral loads that we find in elderly people, it is mind boggling, he said. That has been for me the big surprise with this virus. This will influence how contagious elderly people can be and perhaps is reflected in the high number of Covid-19 clusters in nursing homes, he added.

What else have we learned in recent days?

The virus is also abundant in the throats of younger patients according to viral counts reported in the science journal Nature. Nine young to middle-aged office workers near Munich, Germany, who showed mild flu-like symptoms, had their nose and throat swabbed daily and spit samples collected for viral counts. We detected Sars-CoV-2 in enormous amounts in the upper respiratory tract, said Prof Clemens Wendtner, who led the research in Germany 1,000 times more than for Sars. This was shocking news.

All nine patients showed a high rate of viral replication and shedding in their throat during their first week of infection. The virus does not need to travel to the lungs to replicate, and is abundant in the throat, making it easy to pass on. It can be spread easily by sneezing or coughing, said Prof Wendtner.

The viral loads that people encounter when someone coughs in their general direction, are so high, said Prof Van Ranst, that it makes transmission likely to happen. Compared to other respiratory viruses, this is remarkable, he added. It also meant it was easier for those with even mild symptoms to contaminate surfaces.

The Nature paper confirms that for the milder form of the disease, it doesnt go as far as the lungs, but stays in the throat, said immunologist Prof Luke ONeill of Trinity College Dublin. It means it is very transmissible just by talking. You dont need to cough, he said. Also, people without symptoms, are very infectious, he added. Sars never infected the throat. Went straight to the lungs. So thats a big difference, he explained.

Are men more likely to die than women?

The short answer is yes. With the worldwide death toll closing in on 130,000 it has become clear that men are much more likely to die from coronavirus than women. Charity Global Health 50/50, which campaigns for gender equality in health, has been tracking the breakdown internationally for deaths from the virus. In every country that publishes the data, significantly more men than women have died.

In Italy, which has the highest number of deaths from the disease, men account for 58 per cent of all hospitalised cases and 72 per cent of all deaths. In Spain, men account for 59 per cent of all hospital admissions, 72 per cent of intensive care unit admissions and 65 per cent of all deaths. In China, where the virus first started, 64 per cent of fatalities have been men.

In the Republic men account for less than half (45 per cent) of all confirmed cases, but 71 per cent of deaths.

Why is that?

Irelands deputy chief medical officer Dr Ronan Glynn said there were a number of hypotheses as to why this phenomenon was happening. It is either biology or behaviour or a mixture of both, he said. In some countries significantly greater proportions of men smoke. The activity of smoking is often associated with touching your face. Royal College of Surgeons in Ireland professor of medicine Sam McConkey believes the reasons may be more general.

Its just speculation, but Im happy to speculate that men in general do not look after themselves, he said. We drink too much and we smoke too much and we do not go to the doctor. Women are much better at getting proper diagnosis and taking the proper tablets.

How long will the restrictions be in place?

As it stands the restrictions on movement and social and commercial life in the country will remain in place until May 5th but even then we are only likely to see a partial lifting of the strict regime and that is contingent on the rate of infections continuing to fall.

What does partial mean?

Senior Government officials have begun to work on plans for a phased exit from the lockdown with the priorities expected to include the reopening of more retail businesses, construction and maybe schools although that might only be for some classes and for a portion of the week only.

When the time comes for restrictions to be eased they will be lifted in reverse order with movement and retail looked at first.

Dr Cillian De Gascun, chairperson of the coronavirus expert advisory group, has warned against complacency about the dangers of Covid-19 because given the opportunity this virus will run rampant and he warned that we are not going to return to a normal state of affairs soon.

What else in being considered to bring the pandemic under control here?

Prof McConkey has said the Government was at a crossroads and was faced with two decisions on treating Covid-19. The first option would to continue efforts to flatten the curve over a period of six to nine months while the second choice is more severe and would see a short, sharp response to try to prevent the spread of the virus entirely in Ireland. This move would require a 32-county approach.

It would be challenging. It would mean restricting travel and quarantining people coming into the country, Prof McConkey said. I feel it has to be a national decision, we would have to get Northern Ireland to go with us on this journey. It would have to be an all-island approach. It needs national discussion and involve all the parties in Northern Ireland. This is the approach being adopted in countries such as South Korea and New Zealand.

Will the virus diminish as the summer approaches and temperatures climb?

That was a hope in the very early days of the crisis. While it is getting warmer, experts are no longer holding out much hope that better weather will kill off coronavirus. The flu virus goes into decline in warmer months, and is spread the same way as Covid-19, by way of small mucus droplets suspended in the air. When conditions are warmer, droplets are more likely to fall to the ground and not cause infection which is one reason flu is seasonal and dominant in winter. The other is because exposure to the cold during winter coincides with immune systems being stressed. There is no indication that any of this applies to Covid-19, Prof Kingston Mills from Trinity College told this publications Science Editor Kevin OSullivan. He said it may prove to be the case but caution had to be applied. He pointed out that Spain is a damn sight warmer, and look at what its going through.

Why are some people so infectious and what are superspreaders?

One of the questions scientists have been asking as the virus continues to spread is if some people are more infectious than others and the answer appears to be yes. There do seem to be superspreaders, a loosely defined term for people who infect a disproportionate number of others, whether as a consequence of genetics, social habits or simply being in the wrong place at the wrong time. There are also people who are infected but unlikely to spread the infection.

Two factors are at play, Martina Morris, emeritus professor of statistics and sociology at the University of Washington told the New York Times this week. There has to be a link between people in order to transmit an infection, she says. But, she adds, a link is necessary but not sufficient. The second factor is how infectious a person is. We almost never have independent data on those two things.

If you are the first person in a crowded room to get infected, and if this is an easily spread disease, you will look like a superspreader, she says. Anyone in that room could have had the same impact. You were just the first in line.

Dr Thomas Frieden, former director of the United States Centers for Disease Control and Prevention said superspreading events may involve people with symptoms that linger but who are not sick enough to stay at home. Or they could involve infected people who shed an unusual amount of virus.

People have been attacking 5G masts?

There was a suspected arson attack on two large telecommunications masts in Co Donegal over the bank holiday weekend. Conspiracy theorists have linked new 5G technology to the cause of the global pandemic. The Government here and governments across the EU have all stressed there is absolutely no link between 5G and Covid-19.

What is happening on the economic front?

The coronavirus pandemic has brought the global economy to its knees and is likely to result in the worst economic downturn since the Great Depression, the International Monetary Fund (IMF) has said. In its latest world economic outlook report, it said it expects the global economy to contract sharply by 3 per cent in 2020 with the euro zone, the epicentre of the pandemic for the past month, experiencing a much sharper 7.5 per cent contraction.

Its outlook for Ireland is slightly better though still grim. It expects the economy to contract by 6.8 per cent this year, less severe than the Central Bank projection for an 8 per cent contraction. The IMF expects the Irish economy to bounce back strongly next year, expanding by 6.3 per cent, against a euro-zone average of 4.7 per cent. However, unemployment could prove trickier to ease. The IMF says the jobless rate in Ireland will rise to an average of 12 per cent in 2020, up from a low of 4.8 per cent in February, and will stay elevated at almost 8 per cent in 2021.

What are the unemployment figures in Ireland?

There are 533,000 people registered for the 350 weekly Covid-19 unemployment benefit payment which was introduced in the wake of huge job losses. The take up of a temporary wage subsidy scheme for businesses was continuing to grow, and in total 199 million has been paid out under the scheme to date.

What is being done to aid European economies?

A 500 billion deal was reached between EU finance ministers last week. It has several elements. There is the employment guarantee scheme recently invented by the European Commission. If member states put up 25 per cent collateral, they can get a slice of loans raised by the commission on the market. This would be used to subsidise companies to keep employees on the books. The scheme would be worth a maximum of 100 billion.

There are also loans from the European Investment Bank to support companies: 25 billion of extra guarantees, so it can step up lending by 200 billion.

But the biggest chunk is from the EUs bailout fund, the European Stability Mechanism, which was created to dig out states during the euro zone debt crisis. States can borrow up to 2 per cent of their GDP, with a total of 240 billion available. Usually, taking loans from the ESM comes with the requirement to balance the books known as reforms by supporters, austerity by critics.

This time, borrowing will come without these strict conditions as long as the money is solely for responding to the pandemic and relates directly or indirectly to health spending.

What else is happening?

The European Commission says the new deal should be seen in the context of various other measures, particularly the decision by the European Central Bank to throw off prior restraints to print money, by buying government bonds to keep EU countries liquid. Finance ministers and the commission have also agreed to relax the usual budget rules to give states free rein to spend and support companies, and freed up existing unused funds from the EU budget to be used to respond to the crisis.

What is the Irish Government saying about the deal?

Minister for Finance Paschal Donohoe has said the Government may need limited access to the new European Union Covid-19 rescue package to help fund the wage subsidy scheme and support companies in difficulty.

Mr Donohoe has expressed confidence that the country can create a new economy and create new services to recover and move forward, but he cautioned, we have a journey ahead of us.

The new welfare supports will be monitored and may need to be strengthened to aid the recovery as at least 200,000 workers access the wage subsidy scheme. The Minister said it was possible that Ireland would need to access funds from the European Investment Bank to help fund companies and will consider whether to access the programme to help fund wage subsidy schemes. It is hoped that Ireland will not need to use the fund from the European Stability Mechanism, he added.

What are other people saying?

Alan Ahearne, the professor of economics at NUI Galway said the rescue package was a positive outcome, but warned that the figure needed was likely to increase. Prof Aherne said that as it stands Ireland will not need to borrow from the European Stability Mechanisms new low-cost loan fund, as the European Central Bank keeps borrowing costs close to zero. He said he was cautiously optimistic the recovery would be much, much quicker than a usual recession given the welfare supports that have been put in place.

Is China over the crisis now?

No one thinks the crisis is over in any country in the world. However, the country where the first cases of the virus were recorded more than 100 days ago has made substantial progress in recent days. It reported zero new coronavirus deaths on one day last week for the first time since it started publishing daily figures in January. That is a milestone that offers grounds for some relief as the country works to stave off a second wave and struggles with ongoing outbreaks in Wuhan. The National Health Commission reported 32 new cases across China on Tuesday, all of them imported infections, bringing the number of cases involving overseas travellers to 983.

Are EU countries about to ease restrictions?

Some EU countries are easing some restrictions or at least they will in the days ahead. In Denmark, there is what has been described as a cautious reopening, starting with daycare and primary schools opening. The Danish prime minister Mette Frederiksen has described the process as a bit like walking the tightrope. In Austria, small shops, hardware and gardening stores have been allowed to reopen under certain conditions with all retailers likely to follow from May 1st. Spain and Italy have also started to partially lift restrictions.

The European Commission has urged all EU states to co-ordinate as they begin to ease lockdown measures, warning that failure to do so could result in new spikes of the epidemic.

In a set of recommendations to be adopted this week, the commission said: It is time to develop a well co-ordinated EU exit strategy. The exit strategy should be co-ordinated between the member states, to avoid negative spillover effects.

And when will it all end allowing normality to be restored?

No one can answer that question with any confidence but it is unlikely that all restrictions will be lifted for several months and the aftershocks, in terms of public health, economic life and social activities will be felt for a lot longer than that.

While Mr Harris has raised the prospect of easing some restrictions, he warned: There isnt going to be a magic point at the start of May where life as we knew it before the coronavirus can resume. I think, being truthful, social distancing is going to remain a very big part of life not just in Ireland but the world over until we get to a vaccine or effective treatment for the coronavirus.

He said the key indicators to watch in the coming weeks would be the rate of growth of the virus, the average number of people in intensive care units and the reproductive rate of the virus, which measures how many people each infected person is likely to pass the virus on to.

Here is the original post:

Coronavirus in Ireland: What we know so far - The Irish Times

Hitting the Reset Button on Antibiotics – CTech

Most antibiotic drugs approved in the past decade were similar to one another because they were all developed based on human intuition, according to Regina Barzilay, an Israeli researcher who, together with bioengineer James Collins, headed an MIT team that recently discovered a new, hyper-efficient antibiotic molecule using artificial intelligence.

Barzilays teams discovery, first published in the January edition of peer-reviewed scientific journal Cell, marks the first time in over three decades when a completely new antibiotic molecule was discovered. Called Halicin, the molecule was able to kill two of the most dangerous and durable bacteriasAcinetobacter baumannii and a bacteria from the enterobacteriaceae family. Unlike with other antibiotics, the bacteria failed to develop resistance to Halicin even after 30 consecutive days of treatment.

At the midst of what international health organisations have dubbed the post antibiotic era in which humanity is expected to fight bacteria that has become resilient to conventional treatment, MITs new discovery is nothing short of a revolution. Therefore, it may seem surprising that Barzilay, the leading scientist in the project is not a chemist, a biologist or a medical doctor, but is in fact a computer scientist. Her team focused its efforts on using computers to beat the limitations of human intuition and discover an entirely different drug, the type of which bacteria did not have a chance to familiarize themselves with yet.

According to Barzilay, what the team did was gather a vast range of molecules and test the effect each of them had on delaying the growth of pathogens. The methodology we developed allowed the AI to process the connection between the chemical response and the delay in activity, so that it could predict the effect of new molecules it is exposed to, she said. The system developed by her team scans through a multitude of existing research on known chemical compounds in search of molecules with a potential to function as new antibiotics.

Since 1987, every new antibiotic drug was based on already discovered families of molecular structures that have been used extensively. This becomes a problem as bacteria evolves quickly, developing ever growing resilience against these structures. Since the discovery of penicillin, the first antibiotic compound, early in the previous century, more and more bacteria and viruses have developed resilience and the result is extremely hard to fight superbugs.

The often cited 2016 ONeill report, commissioned by the British government and soon adopted by the United Nations, estimated that, barring a significant leap in addressing antimicrobial resistance, by 2050, 10 million people will die from superbugs every year, costing global economy an accumulated $100 trillion in terms of lost global production. In November, the U.S. Centers for Disease Control and Prevention (CDC) announced the the post antibiotic era has arrived.

As if this werent bad enough, in todays pharmaceutical industry, it is not financially viable to develop new antibiotics. Developing a drug, passing it through regulatory processes, and marketing it, takes an average of 10 years and $1 billion. Despite the public health benefit of introducing new drugs, hospitals and health maintenance organizations (HMOs) are wary to use new and expensive antibiotics, given the readily available cheap options and only do so as a last resort, for short periods of time. This means developing remedies for chronic medical conditions are simply more profitable and this is what both the human and fiscal capital of the industry are focused on.

To exemplify how broken the pharmaceutical market is, one needs to look no further than San Francisco-headquartered late-stage biopharmaceutical company Achaogen Inc. In April 2019, just several months after gaining regulatory approval for a new antibiotic drug it developed, Achaogen, founded in 2002, filed for bankruptcy. Instead of helping the company thrive, the approval brought Achaogens stock down and its sales amounted to a mere $1 million, negligible compared to the required investment.

Shortly thereafter, in January 2020, Melinta Therapeutics Inc. also went bankrupt, after failing to monetize on four drugs. These two boutique companies joined five big pharmaceutical companies that have shut down all of their antibiotic research between 2017 and 2018, bringing the World Health Organization (WHO) to issue a statement earlier this year warning that declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections. The vast majority of the 60 products currently in development, WHO wrote, bring little benefit over existing treatments and very few target the most critical resistant bacteria.

Barzilays team is attempting to bridge this gap between the needs of the general population and the financial needs of commercial companies. The coronavirus crisis shows how desperately we need innovative solutions, Barzilay said. We have to be quick in developing a treatment and one way to do that is to look at existing drugs or a combination of such, she said.

The team used 2,335 different compounds to teach its AI system to make predictions. Each compound was tested on different bacteria to examine the reaction. Once it studied existing drugs, the computer went on to scan massive new databases of moleculesincluding a wide range of drugs and synthetic and natural materialsto detect any compound that could slow down the growth of Escherichia coli (E. Coli). Since only a small portion of the databases the system studied was of antibiotic compounds, the AI system did not develop any prejudice or bias as to how an antibiotic molecule looks like. All it did was scan for molecules that had non-traditional operating mechanisms that allow them to fight infections that have developed resilience to many existing drugs.

Among the molecules it scanned, the system identified 120 promising molecules. Barzilay and the rest of the team then manually filtered out any molecule that resembled existing antibiotics or was known to be poisonous, leaving them with 23 molecules to test. One of the molecules was Halicin, which stood out because its operating mechanismoverlooked by chemists up to this point targeted the bacterias metabolism.

Barzilay, 50, was born in Chisinau, Moldova and immigrated to Israel with her parents at the age of 20. She studied computer science at

Ben- Gurion University of the Negev (BGU) and moved to New York in

1998 for a PhD at Columbia University. She then moved on to a post doctoral fellowship at Cornell University, finally landing in 2003 at MIT, where she is a professor in the computer science department.

Over the years, Barzilay focused on research related to natural language processing, until, in 2016, she was offered to join a research by the chemical engineering department of the U.S. Defense Advanced Research Projects Agency (DARPA). Barzilay said she was curious to get into this field and spent the first two years learning about the most effective ways to design molecules without even thinking about the pharmaceutical industry, that was not using AI for chemical discovery.

Over the years, some pharma companies managed to harness AI tools developed at MIT for various discoveries, but this was not enough, Barzilay said. My problem was that I was not privy to the whole process, she explained. We would give them the tool, the companies would use it, but I did not know what happened with it. That is why she searched for an in-house collaboration in the university that would bring it full circle. This is how the connection with Collins, who is a pioneer in synthetic biology, was made, resulting in the discovery of Halicin.

Machine learning can completely transform the field of chemical discovery, Barzilay said. The current pandemic illustrates how crucial finding the right medicine in time is and it is hard to believe that coronavirus will be the last pandemic, so we have to create mechanisms for designing new molecules on demand, she said.

Over the past month, as almost everyone was confined to their homes and MITs facilities stood empty, Barzilay and Collins team has been hard at work to discover a cure for Covid-19. One of the reasons we were able to conduct the antibiotic experiment so easily was because we had someone in-house that could test different compounds on human cells to see which of them get infected and which do not, Barzilay said. The problem with Covid-19, she said, was that the scans could not be done at MIT as safely handling the virus required special highly secure quarantine facilities and that there wasnt enough accessible data to train the system.

In the last week, however, fragments of information were released by various sources, Barzilay said. Her team combined these fragments with what is known of the 50 drugs that are currently being tested for

Covid-19 and of SARS (Severe acute respiratory syndrome), another of Covid-19s family of viruses to surface in 2004. We developed several methodologies to combine these different groups of information and created a model that is searching for a molecule that has the potential to fight the virus, Barzilay said.

Read the original:

Hitting the Reset Button on Antibiotics - CTech

Mark Cuban and Tyler Winklevoss Squabble Over Bitcoin Complexity – Cointelegraph

Despite being over a decade old, Bitcoin (BTC) is still not particularly easy to understand. Even major BTC bulls like Tim Draper have admitted that Bitcoin still lacks ease of use for mainstream adoption.

In the same vein, two key figures in the community held an informal Twitter debate over Bitcoins complexity today.

Mark Cuban, one of the most well-known Bitcoin sceptics, prefers to own bananas than invest in bitcoins. Cuban previously criticized Bitcoins complexity in an interview with Anthony Pomp Pompliano on April 15. In the interview, the owner of the NBAs Dallas Mavericks reiterated a common Bitcoin complexity narrative, arguing that Bitcoin needs to be easy enough that grandma can use it before mass adoption will occur.

When asked about what would have to happen for him to change his mind about Bitcoin, Cuban answered that it should become easy, elaborating on Bitcoins complexities:

Itd have to be so easy to use, its a no-brainer. Itd have to be completely friction-free and understandable by everybody first. [...] Theres so many peculiarities to Bitcoin: the halving, the mining.

While some in the crypto community agreed that BTC is quite difficult to use, Tyler Winklevoss, a co-founder of major crypto exchange Gemini, decided to weigh in. Winklevoss argued that, for someone without preexisting knowledge of the game, basketball is at least as peculiar as Bitcoin. He tweeted:

Theres so many peculiarities to Bitcoin: the halving, the mining." - @mcuban The rules of basketball are far more peculiar, but that doesn't seem to be holding it back.

It was not long before Cuban reacted to the Winklevoss remark, tweeting the following counter-argument in less than 10 minutes:

One was started by a guy named James in a gym with a peach basket and a ball to entertain kids. The other was started by a guy no one can find, that hundreds claim to be, with a computer and an algorithm to give millions something to argue about. Which is simple?

Winklevoss subsequently argued that both of these origin stories are interesting from a historical perspective,. He then firing out another argument, hinting that nobody really cares about basketball:

My bet is that if you took a poll of all the basketball fans that buy tickets to watch @dallasm games, less than 1% would know that the game they are watching was started by a guy named James trying to entertain kids and 0% would actually care.

After years of scepticism, Cuban delivered a mixed message about Bitcoin in late 2019. As Cointelegraph reported in December, Cuban admitted that Bitcoin could become a reliable financial instrument.

In September 2019, billionaire investor and major Bitcoin bull, Tim Draper, declared that people still prefer fiat money over Bitcoin. He reasoned that fiat money seems to be an easier option to pay for services. According to Draper, Bitcoins inherent difficulty is the main impediment to mass adoption. He further claimed that engineers have not made it that easy enough for everyone to use Bitcoin.

Read the original here:

Mark Cuban and Tyler Winklevoss Squabble Over Bitcoin Complexity - Cointelegraph

Crypto Analyst Cautions Investors Against Bitcoin for 3 Key Reasons – Cointelegraph

Bitcoin is often described as gold 2.0; a superior system of storing and transferring value. It has seen a rapid increase in market capitalization since its introduction in 2009, with strong custodial, exchange, and futures infrastructure.

Yet, one cryptocurrency analyst known as cryptocomicon recently laid out a series of compelling reasons why one should not invest in Bitcon. The three that stood out most were limited privacy, centralized mining, and the lack of scalability.

Despite each of these being valid points to consider, they can also be seen as advantages for BTC.

Up until 2018, governments and various financial bodies criticized the anonymous nature of Bitcoin, stating that it poses a risk to the global financial system. But, as reported by Cointelegraph, South Korea recently cracked down on a large-scale sex crime ring earlier this month through tracking Bitcoin addresses.

One could argue that the lack of privacy measures on the Bitcoin network has actually improved the image of the dominant cryptocurrency.

Previously the public and governments perceived Bitcoin as the currency most preferred for use in criminal activities and terrorist financing, but this view appears to have changed in recent years as sophisticated blockchain analytics companies who offer crypto transaction tracking services emerged.

Following the release of the Financial Action Task Force (FATF)s revised guideline on crypto assets on February 22, 2020, it has become even more challenging to launder money using Bitcoin than ever before.

Thus, the lack of privacy can also be viewed as increased transparency and this could eventually prevent governments from over-regulating Bitcoin-related companies.

The low scalability of Bitcoin is similar to the no privacy argument in the sense that it can be comprehended in two ways: it can make transactions expensive when the network reaches its peak, but it can also encourage second-layer scaling.

Some state that the relatively high fees on the Bitcoin network would push for the use of second-layer scaling solutions, which many believe to be inevitable if public blockchain networks are eventually used by billions of people worldwide.

Other major public blockchain networks with high scalability like Ethereum are exploring second-layer scaling solutions such as plasma, indicating that second-layer scaling is necessary for any large blockchain network.

According to a report from CoinShares Research, up to 65 percent of the Bitcoin network hashpower comes from China, a level unseen since 2017. While the level of mining centralization in China is currently high, over time it is expected to become more distributed across the world.

To date, large mining centers in China have been able to access cheap electricity in mountainous regions of the country, operating ASIC miners at low costs with natural cooling. Consequently, the level of mining centralization in China reached unprecedented levels in December 2019.

Additional data from CoinShares explained that:

While we expect this ratio to fall again as latest generation hardware further makes its way into the non-Chinese market, at the time of writing, as much as 65% of Bitcoin hashpower resides within China the highest weve seen since we began our network monitoring in late 2017.

The researchers also said:

We have reasons to believe the lions share of the newly deployed hardware has been predominantly installed in China. There could be many reasons for this, but Occams Razor suggests that it is likely an effect of relational and geographic proximity to manufacturers making barriers to business comparatively lower.

Chinas Bitcoin mining equipment access and hashrate. Source: CoinShares

Currently Chinas mining sector has two clear advantages over the rest of the world, cheap electricity and direct access to new mining equipment. Eventually, lower electricity rates and better access to newer mining equipment could push the global mining industry to expand outside of China in the years to come, reducing the level of centralization.

More:

Crypto Analyst Cautions Investors Against Bitcoin for 3 Key Reasons - Cointelegraph

Bitcoin: The Halvening Cometh – Forbes

HONG KONG, HONG KONG - NOVEMBER 9: As a visual representation of the digital Cryptocurrency, Bitcoin ... [+] with US Dollar on November 9, 2017 in Hong Kong, Hong Kong. Cryptocurrencies - Bitcoin, have seen unprecedented growth in 2017. (Photo by studioEAST/Getty Images)

Bitcoin remains a controversial asset with most people either believing it as doomed to be valueless or set to be worth $1 million a coin. As such it is probably a fair bet to say it will do neither.

Here is the state of play:

The Bitcoin chart as the 'halvening' approaches

This is what happened last time:

Here's what happened to the Bitcoin price after the last 'halvening'

The idea is that the price will go up because the supply of new coins will halve, so on an even keel basis there will be the same demand but less supply. The increase of bitcoin supply will half but interestingly it will also fall below the recent rate of U.S. dollar inflation. So the thinking goes: supply of new bitcoin down + supply of bitcoin less than U.S. dollars (substantially less since the recent titanic stimulus packages) + ever increasingspread of acceptance = significant price rise.

Doomsters say that miners will flee as they can no longer make money mining and the blockchain will seize up. However, every two weeks the mining difficulty retargets to take that into account, so this scenario simply wont happen and in the end transaction costs would make up for any drop in new coin rewards if the situation became difficult. A $6 per transaction fee would fill the gap, which is super pricey, but not when large transactions are at stake.

The halvening wont break bitcoin, but will it be the beginning of the next leg up?

I think so.

Will it catapult bitcoin to $100,000 a coin? It could happen but I want to believe because I have a pile of bitcoins.

The key factor will be the shape of the developing coronavirus recession. The outcome of these huge stimulus packages are impossible to predict. Not only is their effect utterly unpredictable but even their scale is uncertain. Bitcoin (BTC) is just a tiny sideshow to all these goliath moves.

The only outcome that would hurt BTC is deflationary depression and with trillions of cash being helicoptered in to bailout everyone, at least the deflationary part seems hard to imagine.

What isnt so hard to imagine is something the ex-Federal Reserve Chairman brought up: Hysteresis. Thats not the electrical thing, its the political type. Hysteresis is what Marxists use to explain away the fact that their fabulous theories never seem to be adopted or work. Its a shock to the system that is needed to create the momentum for a sudden and irreversible change. That Ben Benenke should bring up the prospect for that is enough to make your ears burn. Bitcoin $1 million is totally ridiculous but then.

A Zimbabwe one hundred trillion dollar note

Whether hysteresis would mean a trillion dollar bill or something else entirely, it wont do bitcoin any harm.

Love it or hate it, in times of hysteresis a bitcoin wallet would be a prized possession. Even without the halvening, bitcoin looks good as a haven/flight asset in very uncertain times.

-

Clem Chambers is the CEO of private investors websiteADVFN.com and author of 101 Ways to Pick Stock Market Winners and Trading Cryptocurrencies: A Beginners Guide.

Chambers won Journalist of the Year in the Business Market Commentary category in the State Street U.K. Institutional Press Awards in 2018.

Follow this link:

Bitcoin: The Halvening Cometh - Forbes

TOP 3 Bitcoin and Crypto News for Today: 17 April – U.Today

Geoffrey Schwartz

Bitcoin (BTC) price prediction, Binance (BNB) smart chain white paper released, and Nassim Taleb recommends cryptocurrencies.

The last day of the workweek ended in the green for the three major indexes. The Dow Jones Industrial Average (DJIA) rocketed up 704.81 points (about 3%) to close at 24,242.49. The S&P 500 went up 75.01 points (about 2.7%) to close at 2,874.56. The NASDAQ Composite advanced 117.78 points (about 1.4%) to close at 8,650.14. All of this optimism and hope was based on a drug report published by Gilead Sciences, which showed some promise for treating the coronavirus.

As for news within the crypto world, some of the major headlines include a price prediction for Bitcoin (BTC), the release of a Binance (BNB) Smart Chain white paper, and Nassim Taleb recommending the use of cryptocurrencies.

Yesterday morning was strong bullish impulse for the average price of Bitcoin (BTC). As a result, this pushed the BTC/USD pair above the $7,026 mark. By the end of the day, the price of BTC was able to gain a foothold above this support level.

Overnight growth was not supported by large volumes, and a local maximum was set around the $7,224 area. The next morning, the priced rolled back from its maximum.

Looking at the lines from the Stochastic Relative Strength Index (Stoch RSI), the price of BTC is now in the overbought zone. A rollback to the average price region can therefore be expected in the near future. If the 2H EMA55 provides support, then growth may continue to the $7,300 mark.

Yesterdays growth to $7,190 mark closed above $7,000 with a full candle, indicating buyer strength. It is likely not the usual removal of short positions. For the moment, the big picture is an upswing. To confirm this, the bulls need to keep the price above $6,900 and pass the $7,150 resistance level. If that is the case, then traders can expect a significant increase to its previous local maximum of $7,459 or higher.

Binance has broken into the decentralized application market by creating the Binance Smart Chain, a special parallel blockchain to land smart contracts. The Binance Smart Chain, which will be cross-chain interoperable, will use a Proof-of-Stake Authority consensus. As a result, staking the Binance Coin (BNB) will be available to all users.

According to the recently released white paper, the reason a separate chain was required was because:

The execution of a Smart Contract may slow down the exchange function and add non-deterministic factors to trading

While Binance (BNB) is aware of the situation in the dApps market, EOS (EOS), Ethereum (ETH), and Tron (TRX) have managed to address the needs of dApp developers.

With developed countries announcing one stimulus package after another to counteract the effects of the COVID-19 pandemic, some governments are screwing over its citizens. Nassim Nicholas Taleb, author of The Black Swan, highlighted the importance of cryptocurrencies as a tool for cross-border remittances.

According to Pierre Madani, Chief Financial Officer of Kafalat S.A.L., BDL has begun to confiscate hard currencies from over-the-counter remittances because of hyperinflation for the Lebanese Pound (LBP) and the national banks losing credit. Instead of acquiring stable foreign currencies, beneficiaries can only obtain the worthless LBP.

Taleb, a major advocate for Bitcoin (BTC) and other financial institutions involving cryptocurrencies, believes that they could replace the classical remittance and exchange tools in emerging markets. He also applauded the anti-authoritarian nature of Bitcoin (BTC) and other major cryptocurre

See more here:

TOP 3 Bitcoin and Crypto News for Today: 17 April - U.Today

More Investors Are Holding Bitcoin Ahead of the Halving, Data Suggests – CoinDesk

Investors may be accumulating bitcoin ahead of next month's miner reward halving.

The seven-day moving average of the total number of bitcoin held in exchange addresses fell to 2,214,365 on April 14 the lowest level since last June according to numbers from blockchain intelligence firm Glassnode.

As of Tuesday, the average was down nearly 8 percent from a high of 2,404,786 registered on Jan. 17, 2020.

The decline in exchange balances suggests a shift to longer-term holding strategies, according to Glassnode.

That's because investors usually withdraw coins from the exchanges to hold in their personal wallets when prices are expected to rise. Conversely, they tend to move their balances to exchanges in preparation to sell when a price drop is expected or during a price crash.

For instance, bitcoins price fell by 33 percent in the seven days to March 15. At the time, the seven-day average of coins held on exchanges rose from 2,333,279 on March 11 to 2,350,795 on March 18.

However, the spike was short lived and the downturn in exchange balances resumed from March 19.

The increased levels of holding may be associated with bullish expectations tied to bitcoins mining reward halving, scheduled to take effect in just 27 days. The process, aimed at controlling inflation, will reduce rewards per block mined from 12.5 BTC to 6.25 BTC.

Essentially, miners will be adding fewer coins to the ecosystem following the halving. Some analysts think that would create a supply deficit and push up prices.Once bitcoin has its halving next month, we expect prices to rally, carrying the rest of the market with it, said Richard Rosenblum, head of trading at GSR.

Meanwhile, some stock-to-flow models indicate the halving could send bitcoins price to $100,000, as noted in the cryptocurrency platform Lunos weekly market report.

Further, the coronavirus-induced global economic recession and resulting unprecedented monetary and fiscal stimulus launched by the Federal Reserve and the U.S. government, respectively, are widely expected to boost bitcoins appeal as a safe haven asset and a hedge against inflation.

However, some observers have been skeptical about the bullish narrative surrounding bitcoins halving. Bitcoin halving in May 2020 wont do anything to the price. It will be a non-event, Jason Williams, co-founder of digital asset fund Morgan Creek Digital, tweeted in December.

Meanwhile, the cryptocurrency has so far failed to perform as a safe haven asset and has largely moved in line with the equity markets. Since the beginning of March, bitcoins correlation with the S&P and Dow has been unusually high at approximately 0.82, Nicholas Pelecanos, head of trading at NEM Ventures, told CoinDesk.

If the decline in exchange balances is a guide, though, the investor community looks to have some belief in the bullish halving narrative and the long-term value of the cryptocurrency as an inflation hedge.

From a technical analysis standpoint, the cryptocurrencys recovery rally from the March low of $3,867 looks to have run out of steam.

Weekly chart

Bitcoin has failed three times in the last month to keep gains above the 100-week moving average, currently lined up near $7,060.The repeated failure is suggestive of buyer fatigue.

That, coupled with the rising wedge breakdown seen on the daily chart, suggests scope for a downside break of the recent trading range of $6,600$7,200. A range breakdown, if confirmed, would open the doors to $6,100, as discussed Tuesday.

Bitcoin has enjoyed an over-50-percent rally from its mid-March low. The bulls now must sustain the rally at an equal or greater pace in the short term or the bears might take back some serious ground," said NEM Ventures Pelecanos. "Indicators from one of our momentum-based strategies are beginning to show a serious bearish setup that could lead to a 50-percent sell-off, sending prices into the low $3,000s."

Disclosure:The author currently holds no cryptocurrencies.

The leader in blockchain news, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups.

Continued here:

More Investors Are Holding Bitcoin Ahead of the Halving, Data Suggests - CoinDesk

Bitcoin Will Follow Ethereum And Move to Proof-of-Stake, Says Bitcoin Suisse Founder – Cointelegraph

Niklas Nikolajsen, the founder of Swiss crypto broker Bitcoin Suisse, predicts that Bitcoin (BTC) will move to Proof-of-Stake (PoS) once the Ethereum (ETH) network has proved the algorithms success.

Bitcoins current Proof-of-Work (PoW) consensus algorithm the pioneering concept which in fact pre-existed Bitcoin, but has since come to be indissociable from the cryptocurrency will probably change in the future, Nikolajsen argued.

In outtakes from an interview conducted for a German TV documentary recorded back in October 2019, but uploaded on April 6 Nikolajsen said:

[Bitcoins move to Proof-of-Stake] is not planned, but the second-largest cryptocurrency, Ether, will move to a Proof-of-Stake concept that demands vastly less electricity, already in a few months. Im sure, once the technology is proven, that Bitcoin will adapt to it as well.

Once its proven that Proof-of-Stake works well, its a superior system to Proof-of-Work, he said.

In blockchains that use a PoS system, nodes in the network engage in validating blocks, rather than mining them, as in PoW. For PoS, a deterministic algorithm selects block validators based on the number of tokens a given node has staked in their wallet i.e. deposited as collateral in order to compete to add the next block to the chain.

Nikolajsen's prediction that Bitcoin will eventually migrate to a PoS system was made in the context of a discussion of the notoriously high levels of electricity needed to sustain mining on the current network.

He dismissed claims that mining Bitcoin consumes levels of electricity comparable to small nations and also emphasized that mining's energy-intensity is less of an issue than where that energy is produced and how sustainably it is generated.

Moreover, the energy consumption of producing gold Bitcoins proverbial predecessor must be equally acknowledged, Nikolajsen states, as does that in the existing banking system and tech industry:

Which metropolis in the world doesnt have 100-story-high banking towers, glowing in a million different colors all night, and their financial systems, their computers, server rooms. How much energy does Facebook consume? They have 21 huge data centers worldwide, Id say probably more than Bitcoin. The banking system for sure consumes a lot more energy.

The common perception that high energy consumption is an Achilles Heel for Bitcoin has been critiqued by some proponents of clean energy, who, like Nikolajsen, place an emphasis on the sources of power, rather than levels of consumption.

Beyond the energy problem, the PoS vs. PoW debate engages questions of economic fairness, barriers to entry, network security and decentralization.

More:

Bitcoin Will Follow Ethereum And Move to Proof-of-Stake, Says Bitcoin Suisse Founder - Cointelegraph

Bitcoin Price Predicted to Go to $50,000 by Trading Guru Peter Brandt (but Don’t Get Too Excited) – U.Today

Alex Dovbnya

$50,000 or Beanie Babies? Here's what the future holds for Bitcoin, according to Peter Brandt

Peter Brandt has shared his latest take on the Bitcoin (BTC) price, predicting that ithas a 50 percent chance of shooting up to as high as $50,000.

However, this price target is not set in stone since there appears to be the same possibility that the orange coin ends up being just 'another pet rock or Beanie Baby.'

Bitcoin has been likened toBeanie Babiesby everyone and their mother -- from permabears in the likes of Peter Schiff to "Last Week Tonight"host John Oliver.

These chictoysare the ultimate fads of the dotcom bubble in the 1990s.During the peak of the craze, some people were willing to fork out their life savings to buy exclusive items that were nothing but stuffed animals. One Beanie Baby was sold for as much as $15,000.

Whether you believe in the future or Bitcoin (BTC) or not, comparing a decentralized cryptocurrency to a toy bubble might be a bit of a stretch. Besides, there are some exclusive Beanie Babies that will now set you back more than $500,000.

As of recently, Brandt has been sending mixed signals about Bitcoin. The prominent chartist who predicted that BTC could conquer $100,000 this year rapidly changed his tune after the March crash.

Following the events of "Black Thursday,"when BTC erased 50 percent of its value, Brandt tweeted that it was more likely to go to zero.

Moreover, he recently argued that the much-anticipated May was highly overrated.

Read more from the original source:

Bitcoin Price Predicted to Go to $50,000 by Trading Guru Peter Brandt (but Don't Get Too Excited) - U.Today

Are Bitcoin Cash Miners Driving Up the Price of Bitcoin? – Cointelegraph

Bitcoin (BTC) price has been a sight to behold over the last week. After successfully breaking through the resistance of $7,200 on Monday, April 6, all eyes were on the leading digital asset to hold $7K as fresh support, but as soon as the weekend was upon us, the price fell through this floor finding a new temporary bottom of $6,750.

So are these weekend dumps a sign that interest in Bitcoin is waning? Or is this simply whales taking advantage of thinner weekend volume to accumulate before the next big run?

Daily crypto market performance. Source: Coin360.com

BTC USD daily chart. Source: TradingView

Bitcoin keeps finding itself in a descending channel that formed 10 months ago. The last time the king of cryptocurrencies broke out of this channel, it encountered fierce resistance at 5 different levels ranging from $8,750 to $10,500.

Currently, Bitcoin is once more above this channel, with a new ascending channel taking form.From here Bitcoin needs to form support by closing the daily above $7,100 for history to start repeating itself, and this is not the only pattern repeating itself this year.

BTC USD weekly MACD chart Source: TradingView

The Moving Average Divergence Convergence (MACD) indicator on the weekly timeframe looks almost identical to that of Jan. 14, which is when Bitcoin last closed above the descending channel. This resulted in a rally from $9,000 to $10,500.

However, much like the last few days, Bitcoin did fall back into the channel before pushing forward to the yearly high.

At the time this was attributed to the mining difficulty increasing every 2 weeks, a trend that seems to be returning.

BTC mining difficulty. Source: BTC.com

After the Black Thursday event, which saw the price of Bitcoin plummet by 50%, the mining difficulty adjustment dropped by nearly 16%. This was one of the largest drops in a single period that Bitcoin had ever seen.

However, last week saw the difficulty increase by nearly 6% and the next adjustment is already looking to increase by 7%. With only 8 days left to go, its highly probable that this will wipe out the negative adjustment seen this year, so does that mean that price will follow?

If the price action at the beginning of 2020 is anything to go by, it might suggest another big price surge is due over the week ahead.

BCH hashrate chart. Source: BITINFOCHARTS

Last week Bitcoin Cash (BCH) had its halving and this caused a lackluster price spike of about 11% before the digital asset slowly settled back to its pre-halving price. However, as a result of the halving, the hash rate dropped off a cliff as can be seen in the chart above.

The most likely reason for this drop is due to the fact that those mining Bitcoin Cash use exactly the same hardware as Bitcoin miners. So when faced with a 50% reduction in profitability it would make more sense to point your miners to the real Bitcoin.

With more miners heading to the Bitcoin network, it would entirely make sense that the difficulty would start to rise. This is something that I expect to continue happening over the next 30 days ahead of the real Bitcoin halving.

However, this will also lead to the difficulty in mining BCH to plummet, so this little dance is something that will cause some very interesting price action over the coming weeks.

If Bitcoin closes above $7,100 it will be incredibly bullish for the week ahead. Once more $7,200 is the first level of resistance, however, $7,400 and $7,700 are the next two levels holding Bitcoin back from breaking $8,000.

With the growing number of miners driving up the difficulty on the Bitcoin network, a run to $9,200 isnt something that would be unreasonable to expect before the week is over.

It still feels like Bitcoin is recovering too soon and the pullback this weekend doesnt seem like it was enough. Should the weekly candle close below $7,100 I would first be looking at $6,750 and $6,500 as the last levels of support before opening up mid $5k range for buyers to step in.

The views and opinions expressed here are solely those of @officiallykeith and do not necessarily reflect the views of Cointelegraph. Every investment and trading move involves risk. You should conduct your own research when making a decision.

Read the original post:

Are Bitcoin Cash Miners Driving Up the Price of Bitcoin? - Cointelegraph